



(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**
(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2018/03/21
(87) Date publication PCT/PCT Publication Date: 2018/09/27
(85) Entrée phase nationale/National Entry: 2019/09/19
(86) N° demande PCT/PCT Application No.: US 2018/023565
(87) N° publication PCT/PCT Publication No.: 2018/175581
(30) Priorité/Priority: 2017/03/21 (US62/474,358)

(51) Cl.Int./Int.Cl. *A01K 67/027* (2006.01),
C07K 14/705 (2006.01), *C07K 14/775* (2006.01),
G01N 33/48 (2006.01)
(71) Demandeurs/Applicants:
THE JACKSON LABORATORY, US;
INDIANA UNIVERSITY RESEARCH AND
TECHNOLOGY CORPORATION, US
(72) Inventeurs/Inventors:
HOWELL, GARETH, US;
SASNER, MICHAEL, US;
CARTER, GREGORY, US;
LAMB, BRUCE, US
(74) Agent: SMART & BIGGAR LLP

(54) Titre : SOURIS GENETIQUEMENT MODIFIEE EXPRIMANT APOE4 HUMAINE ET TREM2 P.R47H ET PROCEDES D'UTILISATION ASSOCIES
(54) Title: A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 AND MOUSE TREM2 P.R47H AND METHODS OF USE THEREOF




FIG. 3A

(57) **Abrégé/Abstract:**
Genetically modified mice characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non- familial late-onset Alzheimer's disease are provided wherein the genome of the mouse

(57) **Abrégé(suite)/Abstract(continued):**

includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p,R47H (Trem2p) operably linked to a promoter, such that the mouse expresses human APOE4p and mouse Trem2p. Methods are provided for screening for a compound for use in the treatment of Alzheimer's disease using such genetically modified mice.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
27 September 2018 (27.09.2018)(10) International Publication Number
WO 2018/175581 A8

(51) International Patent Classification:

A01K 67/027 (2006.01) *C07K 14/775* (2006.01)
G01N 33/48 (2006.01) *C07K 14/705* (2006.01)

(21) International Application Number:

PCT/US2018/023565

(22) International Filing Date:

21 March 2018 (21.03.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/474,358 21 March 2017 (21.03.2017) US

(71) Applicants: **THE JACKSON LABORATORY** [US/US];
610 Main Street, Bar Harbor, ME 04609 (US). **INDIANA
UNIVERSITY RESEARCH AND TECHNOLOGY**

CORPORATION [US/US]; 518 Indiana Avenue, Indi-
anapolis, IN 46202 (US).

(72) Inventors: **HOWELL, Gareth**; 10 Brendun Lane, Mount
Desert, ME 04660 (US). **SASNER, Michael**; 116
Ledgelawn Ave., Bar Harbor, ME 04609 (US). **CARTER,
Gregory**; Po Box 432, Seal Harbor, ME 04675 (US).
LAMB, Bruce; 10487 Windermere, Carmel, IN 46032
(US).

(74) Agent: **DIPIETRANTONIO, Heather, J.** et al.; Wolf,
Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston,
Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,

(54) Title: A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 AND MOUSE Trem2 p.R47H AND METHODS OF USE THEREOF




FIG. 3A

(57) Abstract: Genetically modified mice characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non- familial late-onset Alzheimer's disease are provided wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p,R47H (Trem2p) operably linked to a promoter, such that the mouse expresses human APOE4p and mouse Trem2p. Methods are provided for screening for a compound for use in the treatment of Alzheimer's disease using such genetically modified mice.

[Continued on next page]

WO 2018/175581 A8

KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:

27 December 2018 (27.12.2018)

(15) Information about Correction:

see Notice of 27 December 2018 (27.12.2018)

Previous Correction:

see Notice of 01 November 2018 (01.11.2018)

- 1 -

A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 AND MOUSE Trem2 p.R47H AND METHODS OF USE THEREOF

REFERENCE TO RELATED APPLICATION

[0001] This application claims priority from U.S. Provisional Patent Application Serial No. 62/474,358, filed March 21, 2017, the entire content of which is incorporated herein by reference.

5

GOVERNMENT SUPPORT

[0002] This invention was made with government support under AG054345 awarded by the National Institutes of Health. The government has certain rights in the invention.

10

FIELD OF THE INVENTION

[0003] The present invention relates generally to genetically modified mice useful as models of human Alzheimer disease. In specific aspects, the present invention relates to genetically modified mice expressing human APOE4 and mouse Trem2 p.R47H and methods of use thereof.

15

BACKGROUND OF THE INVENTION

[0004] One of the major obstacles to developing therapies for Alzheimer's disease (AD) is the lack of animal models to be used in preclinical trials. One reason for this may be that existing models are based on familial mutations, while the vast majority of the clinical population has non-familial late-onset AD.

20

[0005] Familial or early-onset Alzheimer's disease is caused by mutations in, or overexpression of, the amyloid precursor protein (*APP*) gene or mutations in presenilin genes (*PSEN1* or *PSEN2*). All of these lead to increased production of the Abeta42 peptide, which is thought to be neurotoxic. Dozens if not hundreds of mouse models that mimic aspects of familial Alzheimer's disease have been created. Many treatments have been shown to be effective in these familial Alzheimer's disease mouse models, but none have been effective when tested in clinical trials.

25

[0006] In contrast, late-onset Alzheimer's disease, which accounts for 95-98% of the human Alzheimer's disease patient population, does not have a simple and defined genetic etiology. Late-onset Alzheimer's disease is thought to be a multifactorial syndrome caused

30

- 2 -

by a variety of genetic and environmental causes interacting with the aging process. Because of this complexity, the genetic causes are still not fully understood and no useful mouse models of late-onset Alzheimer's disease in humans have been reported to date.

SUMMARY OF THE INVENTION

[0007] A genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, and wherein the mouse expresses human APOE4p and mouse Trem2p. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p.

[0008] A genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse expresses human APOE4p and mouse Trem2p, and wherein the APOE4p includes an amino acid sequence of: SEQ ID NO:1, or the APOE4p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:2 under highly stringent hybridization conditions. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p.

[0009] A genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a

- 3 -

promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse expresses human APOE4p and mouse Trem2p, and wherein the mouse Trem2p includes an amino acid sequence of: SEQ ID NO:3, or the mouse Trem2p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:4 under highly stringent hybridization conditions. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p.

[0010] A genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse expresses human APOE4p and mouse Trem2p, wherein the APOE4p includes an amino acid sequence of: SEQ ID NO:1, or the APOE4p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:2 under highly stringent hybridization conditions, and wherein the mouse Trem2p includes an amino acid sequence of: SEQ ID NO:3, or the mouse Trem2p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:4 under highly stringent hybridization conditions. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p.

[0011] A genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genetically modified mouse is a B6(SJL)-*ApoE*^{tm1.1(APOE*4)AdinJ} *Trem2*^{em1AdinJ} mouse whose genome includes: 1) a DNA sequence encoding human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p, and wherein the mouse expresses human APOE4p and mouse Trem2p.

- 4 -

[0012] A method for screening for a treatment for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a treatment to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, and wherein the mouse expresses human APOE4p and mouse Trem2p; and assessing an effect of the treatment on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p. According to aspects of the present invention, assessing an effect of the treatment includes comparing the effect of the treatment on the genetically modified mouse with a control. According to aspects of the present invention, the control includes administering the treatment to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the treatment on the mouse which does not express human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the treatment to a wild-type C57BL/6J mouse and assessing an effect of the treatment on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the treatment to an APOE3-expressing mouse and assessing an effect of the treatment on the APOE3-expressing mouse.

[0013] A method for screening for a treatment for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a treatment to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter,

- 5 -

wherein the mouse expresses human APOE4p and mouse Trem2p, and wherein the APOE4p includes an amino acid sequence of: SEQ ID NO:1, or the APOE4p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:2 under highly stringent hybridization conditions; and assessing an effect of the treatment on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p. According to aspects of the present invention, assessing an effect of the treatment includes comparing the effect of the treatment on the genetically modified mouse with a control. According to aspects of the present invention, the control includes administering the treatment to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the treatment on the mouse which does not express human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the treatment to a wild-type C57BL/6J mouse and assessing an effect of the treatment on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the treatment to an APOE3-expressing mouse and assessing an effect of the treatment on the APOE3-expressing mouse.

[0014] A method for screening for a treatment for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a treatment to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse expresses human APOE4p and mouse Trem2p, and wherein the mouse Trem2p includes an amino acid sequence of: SEQ ID NO:3, or the mouse Trem2p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:4 under highly stringent hybridization conditions; and assessing an effect of the treatment on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p

- 6 -

and for the DNA sequence encoding Trem2p. According to aspects of the present invention, assessing an effect of the treatment includes comparing the effect of the treatment on the genetically modified mouse with a control. According to aspects of the present invention, the control includes administering the treatment to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the treatment on the mouse which does not express human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the treatment to a wild-type C57BL/6J mouse and assessing an effect of the treatment on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the treatment to an APOE3-expressing mouse and assessing an effect of the treatment on the APOE3-expressing mouse.

[0015] A method for screening for a treatment for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a treatment to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse expresses human APOE4p and mouse Trem2p, wherein the APOE4p includes an amino acid sequence of: SEQ ID NO:1, or the APOE4p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:2 under highly stringent hybridization conditions, and wherein the mouse Trem2p includes an amino acid sequence of: SEQ ID NO:3, or the mouse Trem2p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:4 under highly stringent hybridization conditions; and assessing an effect of the treatment on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p. According to aspects of the present invention, assessing an effect of the treatment includes comparing the effect of the treatment on the genetically modified mouse with a control. According to aspects of the present invention, the control includes

- 7 -

administering the treatment to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the treatment on the mouse which does not express human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the treatment to a wild-type C57BL/6J mouse and assessing an effect of the treatment on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the treatment to an APOE3-expressing mouse and assessing an effect of the treatment on the APOE3-expressing mouse.

[0016] A method for screening for a treatment for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a treatment to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genetically modified mouse is a B6(SJL)-*ApoE^{tm1.1(APOE*4)}Adng/Trem2^{em1/Adng}/J* mouse whose genome includes: 1) a DNA sequence encoding human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p, and wherein the mouse expresses human APOE4p and mouse Trem2p; and assessing an effect of the treatment on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, assessing an effect of the treatment includes comparing the effect of the treatment on the genetically modified mouse with a control. According to aspects of the present invention, the control includes administering the treatment to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the treatment on the mouse which does not express human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the treatment to a wild-type C57BL/6J mouse and assessing an effect of the treatment on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the treatment to an APOE3-expressing mouse and assessing an effect of the treatment on the APOE3-expressing mouse.

[0017] A method for screening for a compound for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a

- 8 -

compound to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, and wherein the mouse expresses human APOE4p and mouse Trem2p; and assessing an effect of the compound on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p. According to aspects of the present invention, assessing an effect of the compound includes comparing the effect of the compound on the genetically modified mouse with a control. According to aspects of the present invention, the control includes administering the compound to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the compound on the mouse which does not express human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the compound to a wild-type C57BL/6J mouse and assessing an effect of the compound on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the compound to an APOE3-expressing mouse and assessing an effect of the compound on the APOE3-expressing mouse.

[0018] A method for screening for a compound for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a compound to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse expresses human APOE4p and mouse Trem2p, and wherein the APOE4p includes an amino acid sequence of: SEQ ID NO:1, or the APOE4p is encoded by the

- 9 -

complement of a nucleic acid which hybridizes to SEQ ID NO:2 under highly stringent hybridization conditions; and assessing an effect of the compound on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p. According to aspects of the present invention, assessing an effect of the compound includes comparing the effect of the compound on the genetically modified mouse with a control. According to aspects of the present invention, the control includes administering the compound to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the compound on the mouse which does not express human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the compound to a wild-type C57BL/6J mouse and assessing an effect of the compound on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the compound to an APOE3-expressing mouse and assessing an effect of the compound on the APOE3-expressing mouse.

[0019] A method for screening for a compound for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a compound to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse expresses human APOE4p and mouse Trem2p, and wherein the mouse Trem2p includes an amino acid sequence of: SEQ ID NO:3, or the mouse Trem2p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:4 under highly stringent hybridization conditions; and assessing an effect of the compound on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p. According to aspects of the present invention, assessing an effect of the compound includes comparing the effect of the compound on the

- 10 -

genetically modified mouse with a control. According to aspects of the present invention, the control includes administering the compound to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the compound on the mouse which does not express human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the compound to a wild-type C57BL/6J mouse and assessing an effect of the compound on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the compound to an APOE3-expressing mouse and assessing an effect of the compound on the APOE3-expressing mouse.

[0020] A method for screening for a compound for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a compound to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse expresses human APOE4p and mouse Trem2p, wherein the APOE4p includes an amino acid sequence of: SEQ ID NO:1, or the APOE4p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:2 under highly stringent hybridization conditions, and wherein the mouse Trem2p includes an amino acid sequence of: SEQ ID NO:3, or the mouse Trem2p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:4 under highly stringent hybridization conditions; and assessing an effect of the compound on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p. According to aspects of the present invention, assessing an effect of the compound includes comparing the effect of the compound on the genetically modified mouse with a control. According to aspects of the present invention, the control includes administering the compound to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the compound on the mouse which does not express

- 11 -

human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the compound to a wild-type C57BL/6J mouse and assessing an effect of the compound on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the compound to an APOE3-expressing mouse and assessing an effect of the compound on the APOE3-expressing mouse.

[0021] A method for screening for a compound for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a compound to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genetically modified mouse is a B6(SJL)-*Apoe*^{tm1.1(APOE*4)AdinJ}*Trem2*^{em1AdinJ/J} mouse whose genome includes: 1) a DNA sequence encoding human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p, and wherein the mouse expresses human APOE4p and mouse Trem2p; and assessing an effect of the compound on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p. According to aspects of the present invention, assessing an effect of the compound includes comparing the effect of the compound on the genetically modified mouse with a control. According to aspects of the present invention, the control includes administering the compound to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the compound on the mouse which does not express human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the compound to a wild-type C57BL/6J mouse and assessing an effect of the compound on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the compound to an APOE3-expressing mouse and assessing an effect of the compound on the APOE3-expressing mouse.

- 12 -

BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 is a schematic diagram of a humanized ApoE4 expression construct described in detail in examples herein.

5 [0023] Figure 2 is an image of a Western blot of brain tissue from B6(SJL)-*ApoE*^{tm1.1(APOE*4)Adiuj} *Trem2*^{em1Adiuj}/J (common name: B6J.APOE4/Trem2) mice (lanes 4-6) and control (wild-type (WT) C57BL/6J (abbreviated B6J) mice (lanes 1-3) brain tissue.

[0024] Figure 3A is a graph showing results of an assay for high density lipoprotein (HDL) in blood samples obtained from 12 month old B6J.APOE4/Trem2 mice and 12 month
10 old C57BL/6J control mice.

[0025] Figure 3B is a graph showing results of an assay for low density lipoprotein (LDL) in blood samples obtained from 12 month old B6J.APOE4/Trem2 mice and 12 month old C57BL/6J control mice.

[0026] Figure 3C is a graph showing results of an assay for total cholesterol in blood
15 samples obtained from 12 month old B6J.APOE4/Trem2 mice and 12 month old C57BL/6J control mice.

[0027] Figure 4 shows representative images of B6J.APOE4/Trem2 tissue at 7-8 months of age immunostained to show Collagen IV (Col IV) and Fibrin(ogen) along with representative images from similar sagittal sections of brain from control C57BL/6J
20 (abbreviated B6J) mice which were similarly immunostained.

[0028] Figure 5 is a gene expression heatmap of differentially-expressed genes in B6J.APOE4/Trem2 mice compared to wild-type control B6J mice.

DETAILED DESCRIPTION OF THE INVENTION

25 [0029] The present invention relates generally to a genetically modified mouse which is a model of non-familial late-onset Alzheimer's disease and which encodes two exogenously introduced risk factors for non-familial late-onset AD in its genome, such that the mouse produces human apolipoprotein E4 (APOE4) and mouse Trem2 p.R47H proteins.

[0030] Human apolipoprotein is a polymorphic protein with three isoforms designated
30 ApoE2, ApoE3 and ApoE4. These three isoforms differ from each other with respect to the identity of amino acids at positions 130 and 176 in the amino acid sequence of the proteins (corresponding to positions 112 and 158 in the mature APOE protein without the 18 amino acid signal peptide). ApoE2 is characterized by cysteine at both 130 and 176, ApoE3 is

- 13 -

characterized by cysteine at 130 and arginine at 176 and ApoE4 is characterized by arginine at both 130 and 176. Individuals having one or more ApoE4 alleles are at greater risk for developing non-familial late-onset AD and a number of mechanisms relating to pathology have been proposed, see for example, DiBattista *et al.*, 2016, Exp. Neurol. 280:97-105; Bu *et al.*, Nature Reviews Neuroscience, 2009, 10:333-344; Huang *et al.*, Cell, 2017, 168:1-15; and Tambini *et al.*, EMBO Reports, 2016, 17:27-36.

[0031] Trem2 (triggering receptor expressed on myeloid cells 2) is an immune phagocytic receptor expressed by brain microglia. Trem2 triggers phagocytosis of cell debris and regulates aspects of the inflammatory response. A rare variant in *TREM2*, p.R47H, is significantly associated with Alzheimer's disease in humans.

[0032] In specific embodiments, the present invention relates to a genetically modified mouse whose genome includes a DNA sequence encoding human APOE4 protein and a DNA sequence encoding mouse Trem2 protein having the R47H point mutation.

[0033] A human *APOE4* DNA sequence (hereinafter APOE4g) encoding human APOE4 protein (hereinafter APOE4p or "human APOE4") is shown herein as SEQ ID NO:2. An encoded APOE4p is shown herein as SEQ ID NO:1.

[0034] A mouse mutant *Trem2* DNA sequence (hereinafter Trem2g) encoding mouse Trem2 protein having the R47H point mutation (hereinafter Trem2p or "mouse Trem2p") is shown herein as SEQ ID NO:4. An encoded Trem2p is shown herein as SEQ ID NO:3.

[0035] One or more genetic modifications can be introduced into a mouse genome to encode a variant of APOE4p and/or a variant of Trem2p in a genetically modified mouse according to embodiments of methods of the present invention.

[0036] As used herein, the term "variant" refers to APOE4p or Trem2p containing one or more mutations in its amino acid sequence compared to the corresponding protein of SEQ ID NO:1 or SEQ ID NO:3. For example, such mutations can be one or more amino acid substitutions, additions, and/or deletions, so long as the variant of APOE4p or Trem2p retains the functional characteristics of APOE4p or Trem2p of SEQ ID NO:1 or SEQ ID NO:3, respectively.

[0037] In particular embodiments, a variant APOE4p according to embodiments of the present invention has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater identity to SEQ ID NO:1 over its entire length, and has R (Arginine) and R (Arginine) as amino acids 130 and 176 of the APOE4 protein including an 18 amino acid signal peptide,

- 14 -

shown herein as SEQ ID NO:1, as well as retains the functional characteristics of APOE4p of SEQ ID NO:1.

[0038] In particular embodiments, a variant APOE4p according to embodiments of the present invention has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater identity to SEQ ID NO:15 over its entire length, and has R (Arginine) and R (Arginine) as amino acids 112 and 158 of the APOE4 protein not including the 18 amino acid signal peptide, shown herein as SEQ ID NO:15, as well as retains the functional characteristics of APOE4p of SEQ ID NO:15.

[0039] In particular embodiments, a variant Trem2p according to embodiments of the present invention has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater identity to SEQ ID NO:3 over its entire length and retains the functional characteristics of Trem2p of SEQ ID NO:3.

[0040] Mutations can be introduced using standard molecular biology techniques, such as CRISPR technology. Alternative techniques include site-directed mutagenesis and PCR-mediated mutagenesis and the like. One of skill in the art will recognize that one or more amino acid mutations can be introduced without altering the functional properties of APOE4p and mouse Trem2p proteins.

[0041] Assays for assessment of functional properties of APOE4p, Trem2p and variants are known in the art.

[0042] Conservative amino acid substitutions can be made in APOE4p and Trem2p proteins to produce APOE4p and Trem2p variants. Conservative amino acid substitutions are art recognized substitutions of one amino acid for another amino acid having similar characteristics. For example, each amino acid may be described as having one or more of the following characteristics: electropositive, electronegative, aliphatic, aromatic, polar, hydrophobic and hydrophilic. A conservative substitution is a substitution of one amino acid having a specified structural or functional characteristic for another amino acid having the same characteristic. Acidic amino acids include aspartate, glutamate; basic amino acids include histidine, lysine, arginine; aliphatic amino acids include isoleucine, leucine and valine; aromatic amino acids include phenylalanine, glycine, tyrosine and tryptophan; polar amino acids include aspartate, glutamate, histidine, lysine, asparagine, glutamine, arginine, serine, threonine and tyrosine; and hydrophobic amino acids include alanine, cysteine, phenylalanine, glycine, isoleucine, leucine, methionine, proline, valine and tryptophan; and conservative substitutions include substitution among amino acids within each group. Amino

- 15 -

acids may also be described in terms of relative size, alanine, cysteine, aspartate, glycine, asparagine, proline, threonine, serine, valine, all typically considered to be small.

[0043] APOE4p and Trem2p variants can include synthetic amino acid analogs, amino acid derivatives and/or non-standard amino acids, illustratively including, without limitation, alpha-aminobutyric acid, citrulline, canavanine, cyanoalanine, diaminobutyric acid, diaminopimelic acid, dihydroxy-phenylalanine, djenkolic acid, homoarginine, hydroxyproline, norleucine, norvaline, 3-phosphoserine, homoserine, 5-hydroxytryptophan, 1-methylhistidine, 3-methylhistidine, and ornithine.

[0044] It will be appreciated by those of ordinary skill in the art that, due to the degenerate nature of the genetic code, nucleic acid sequences other than SEQ ID NO:2 and SEQ ID NO:4 encode APOE4p and Trem2p, respectively, and that such alternate nucleic acids may be introduced into a mouse genome to produce a genetically modified mouse expressing APOE4p and Trem2p of the disclosure.

[0045] The singular terms "a," "an," and "the" are not intended to be limiting and include plural referents unless explicitly stated otherwise or the context clearly indicates otherwise.

[0046] The terms "expressing" and "expresses" refer to transcription of a gene to produce a corresponding mRNA and/or translation of the mRNA to produce the corresponding protein.

[0047] APOE4p and Trem2p variants are encoded by nucleic acids having a high degree of identity with SEQ ID NO:2 or SEQ ID NO:4, respectively. The complement of a nucleic acid encoding an APOE4p variant specifically hybridizes with SEQ ID NO:2 encoding APOE4p under high stringency conditions. The complement of a nucleic acid encoding a Trem2p variant specifically hybridizes with SEQ ID NO:4 encoding Trem2p under high stringency conditions.

[0048] The term "nucleic acid" refers to RNA or DNA molecules having more than one nucleotide in any form including single-stranded, double-stranded, oligonucleotide or polynucleotide. The term "nucleotide sequence" refers to the ordering of nucleotides in an oligonucleotide or polynucleotide in a single-stranded form of nucleic acid.

[0049] The terms "hybridization" and "hybridizes" refer to pairing and binding of complementary nucleic acids. Hybridization occurs to varying extents between two nucleic acids depending on factors such as the degree of complementarity of the nucleic acids, the melting temperature, T_m , of the nucleic acids and the stringency of hybridization conditions, as is well known in the art.

- 16 -

[0050] The term “stringency of hybridization conditions” refers to conditions of temperature, ionic strength, and composition of a hybridization medium with respect to particular common additives such as formamide and Denhardt’s solution. Determination of particular hybridization conditions relating to a specified nucleic acid is routine and is well known in the art, for instance, as described in J. Sambrook and D.W. Russell, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press; 3rd Ed., 2001; and F.M. Ausubel, Ed., *Short Protocols in Molecular Biology*, Current Protocols; 5th Ed., 2002. High stringency hybridization conditions are those which only allow hybridization of substantially complementary nucleic acids. Typically, nucleic acids having about 85-100% complementarity are considered highly complementary and hybridize under high stringency conditions. Intermediate stringency conditions are exemplified by conditions under which nucleic acids having intermediate complementarity, about 50-84% complementarity, as well as those having a high degree of complementarity, hybridize. In contrast, low stringency hybridization conditions are those in which nucleic acids having a low degree of complementarity hybridize.

[0051] The terms “specific hybridization” and “specifically hybridizes” refer to hybridization of a particular nucleic acid to a target nucleic acid without substantial hybridization to nucleic acids other than the target nucleic acid in a sample.

[0052] Stringency of hybridization and washing conditions depends on several factors, including the T_m of the probe and target and ionic strength of the hybridization and wash conditions, as is well-known to the skilled artisan. Hybridization and conditions to achieve a desired hybridization stringency are described, for example, in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, 2001; and Ausubel, F. *et al.*, (Eds.), *Short Protocols in Molecular Biology*, Wiley, 2002.

[0053] An example of high stringency hybridization conditions is hybridization of nucleic acids over about 100 nucleotides in length in a solution containing 6X SSC, 5X Denhardt’s solution, 30% formamide, and 100 micrograms/ml denatured salmon sperm at 37°C overnight followed by washing in a solution of 0.1X SSC and 0.1% SDS at 60°C for 15 minutes. SSC is 0.15M NaCl/0.015M Na citrate. Denhardt’s solution is 0.02% bovine serum albumin/0.02% FICOLL/0.02% polyvinylpyrrolidone.

[0054] The term “complementary” refers to Watson-Crick base pairing between nucleotides and specifically refers to nucleotides hydrogen bonded to one another with thymine or uracil residues linked to adenine residues by two hydrogen bonds and cytosine

- 17 -

and guanine residues linked by three hydrogen bonds. In general, a nucleic acid includes a nucleotide sequence described as having a "percent complementarity" to a specified second nucleotide sequence. For example, a nucleotide sequence may have 80%, 90%, or 100% complementarity to a specified second nucleotide sequence, indicating that 8 of 10, 9 of 10 or 10 of 10 nucleotides of a sequence are complementary to the specified second nucleotide sequence. For instance, the nucleotide sequence 3'-TCGA-5' is 100% complementary to the nucleotide sequence 5'-AGCT-3'. Further, the nucleotide sequence 3'-TCGA- is 100% complementary to a region of the nucleotide sequence 5'-TTAGCTGG-3'.

[0055] To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino acid or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity=number of identical overlapping positions/total number of positions X100%). In one embodiment, the two sequences are the same length or differ in length by no more than 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10% of the total length of the reference sequence.

[0056] The determination of percent identity between two sequences can also be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul, 1990, PNAS 87:2264 2268, modified as in Karlin and Altschul, 1993, PNAS. 90:5873 5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul *et al.*, 1990, J. Mol. Biol. 215:403. BLAST nucleotide searches are performed with the NBLAST nucleotide program parameters set, e.g., for score=100, wordlength=12 to obtain nucleotide sequences homologous to a nucleic acid molecules of the present invention. BLAST protein searches are performed with the XBLAST program parameters set, e.g., to score 50, wordlength=3 to obtain amino acid sequences homologous to a protein molecule of the present invention. To obtain gapped alignments for comparison purposes, Gapped BLAST are utilized as described in Altschul *et al.*, 1997, Nucleic Acids Res. 25:3389 3402. Alternatively, PSI BLAST is used to perform an iterated search which

- 18 -

detects distant relationships between molecules (Id.). When utilizing BLAST, Gapped BLAST, and PSI Blast programs, the default parameters of the respective programs (e.g., of XBLAST and NBLAST) are used (see, e.g., the NCBI website). Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the
5 algorithm of Myers and Miller, 1988, CABIOS 4:11 17. Such an algorithm is incorporated in the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 is used.

[0057] The percent identity between two sequences is determined using techniques
10 similar to those described above, with or without allowing gaps. In calculating percent identity, typically only exact matches are counted.

[0058] Nucleic acids encoding APOE4p, Trem2p or a variant of either thereof can be isolated from natural sources, generated recombinantly or made by chemical synthetic techniques using well-known methodology.

15 [0059] Genetically modified mice

[0060] A genetically modified mouse is provided according to embodiments of the present invention whose genome includes a nucleic acid encoding APOE4p operably linked to a promoter, wherein the animal expresses the encoded APOE4p, and whose genome includes a nucleic acid encoding Trem2p operably linked to a promoter, wherein the animal
20 expresses the encoded Trem2p.

[0061] A genetically modified mouse is provided according to embodiments of the present invention whose genome includes a nucleic acid encoding APOE4p operably linked to the endogenous mouse Apoe promoter, wherein the animal expresses the encoded APOE4p and whose genome includes a nucleic acid encoding Trem2p operably linked to the
25 endogenous mouse Trem2 promoter, wherein the animal expresses the encoded Trem2p.

[0062] Any of various methods can be used to introduce a genetic modification into a mouse genome to produce a genetically modified mouse expressing APOE4p and Trem2p.

[0063] Genome editing methods for generating a genetically modified mouse according to embodiments of the present invention whose genome includes a nucleic acid encoding
30 APOE4p operably linked to a promoter, wherein the animal expresses the encoded APOE4p and whose genome includes a nucleic acid encoding Trem2p operably linked to a promoter, wherein the animal expresses the encoded Trem2p, include, but are not limited to, site directed mutagenesis, recombination-based methods and nuclease genome editing techniques.

- 19 -

[0064] Genome editing techniques can be used to modify a genomic sequence by introduction of a discrete mutation at a predetermined target site in the genome.

[0065] For example, one or more nucleotides in a genomic sequence can be replaced with one or more different nucleotides using a genome editing technique so that the genomic
5 sequence encodes a protein with a single amino acid difference, or multiple amino acid differences, compared to the unmodified genomic sequence.

[0066] Genome editing techniques can also be used to modify a genomic sequence by insertion of a coding sequence into the genome at a predetermined target site, a “knock-in” technique.

10 [0067] As used herein, the terms “target site” and “target sequence” in the general context of a genetic editing technique refer to a nucleic acid sequence that defines a portion of a chromosomal sequence to be edited.

[0068] For example, a nucleic acid sequence encoding a protein can be inserted at a predetermined target site in the genome so that the genome includes a nucleic acid encoding
15 the protein and the protein is expressed. The nucleic acid sequence can also contain a promoter to drive expression of the encoded protein or expression of the encoded protein can be driven by an endogenous promoter when the nucleic acid is inserted in a position so that it is operably linked to the endogenous promoter.

[0069] According to particular aspects of the present invention, a point mutation is
20 introduced into the genome of a first mouse using a genome editing technique so that the mouse encodes Trem2p, and a nucleic acid encoding human APOE4 is inserted into the Apoe4 gene in the genome of a second mouse by a “knock-in” genome editing technique so that the genome of the second mouse contains a “humanized” APOE4 gene as shown in Figure 1, containing exon 1 of the mouse Apoe4 gene and exons 2, 3 and 4 of the human
25 APOE4 gene. The first and second mice are then bred, naturally or by artificial methods, to obtain a genetically modified mouse whose genome includes a DNA sequence encoding APOE4p and a DNA sequence encoding Trem2p.

[0070] According to particular aspects of the present invention, a point mutation is introduced into the genome of a first mouse using CRISPR genome editing technique so that
30 the mouse encodes Trem2p, and a nucleic acid encoding human APOE4 is introduced into the Apoe4 gene in the genome of a second mouse by a “knock-in” CRISPR genome editing technique so that the genome of the second mouse contains a “humanized” APOE4 gene as shown in Figure 1, containing exon 1 of the mouse Apoe4 gene and exons 2, 3 and 4 of the

- 20 -

human APOE4 gene. The first and second mice are then bred naturally or by artificial methods to produce a genetically modified mouse whose genome includes a DNA sequence encoding APOE4p and a DNA sequence encoding Trem2p.

[0071] Genomic editing is performed, for example, by methods described herein, and as detailed in J. P. Sundberg and T. Ichiki, Eds., *Genetically Engineered Mice Handbook*, CRC Press; 2006; M. H. Hofker and J. van Deursen, Eds., *Transgenic Mouse Methods and Protocols*, Humana Press, 2002; A. L. Joyner, *Gene Targeting: A Practical Approach*, Oxford University Press, 2000; *Manipulating the Mouse Embryo: A Laboratory Manual*, 3rd edition, Cold Spring Harbor Laboratory Press; December 15, 2002, ISBN-10: 0879695919; Kursad Turksen (Ed.), *Embryonic stem cells: methods and protocols in Methods Mol Biol.* 2002;185, Humana Press; *Current Protocols in Stem Cell Biology*, ISBN: 978047015180; Meyer et al., *PNAS USA*, 2010, vol. 107 (34), 15022–15026; and Doudna, J. et al. (eds.) *CRISPR-Cas: A Laboratory Manual*, 2016, CSHP. A brief description of several genomic editing techniques is described herein.

[0072] Nuclease Techniques for Genetic Modification of Mice

[0073] A genetic modification method, such as but not limited to, a nuclease genetic editing technique, can be used to introduce a desired DNA sequence into the genome at a predetermined target site, such as methods using a homing endonuclease, integrase, meganuclease, transposon, nuclease-mediated process using a zinc finger nuclease (ZFN), a Transcription Activator-Like (TAL), a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas, or Drosophila Recombination-Associated Protein (DRAP). Briefly, a genetic modification method that can be used includes introducing into an ES cell, iPS cell, somatic cell, fertilized oocyte or embryo, RNA molecules encoding a targeted TALEN, ZFN, CRISPR or DRAP and at least one oligonucleotide, then selecting for an ES cell, iPS cell, somatic cell, fertilized oocyte or embryo with the desired genetic modification.

[0074] For example, a desired nucleic acid sequence can be introduced into the genome of a mouse at a predetermined target site by a nuclease technique, such as, but not limited to, CRISPR methodology, TAL (transcription activator-like) Effector methodology, Zinc Finger-Mediated Genome Editing or DRAP to produce a genetically modified mouse provided according to embodiments of the present invention whose genome includes a nucleic acid encoding APOE4p operably linked to a promoter, wherein the animal expresses the encoded APOE4p and whose genome includes a nucleic acid encoding Trem2p operably linked to a promoter, wherein the animal expresses the encoded Trem2p.

[0075] As used herein, the terms “target site” and “target sequence” in the context of a nuclease genetic editing technique refer to a nucleic acid sequence that defines a portion of a chromosomal sequence to be edited and to which a nuclease is engineered to recognize and bind, provided sufficient conditions for binding exist.

5 [0076] *CRISPR-Cas System*

[0077] CRISPRs (Clustered Regularly Interspaced Short Palindromic Repeats) are loci containing multiple short direct repeats that are found in the genomes of approximately 40% of sequenced bacteria and 90% of sequenced archaea and confer resistance to foreign DNA elements, see Horvath, 2010, *Science*, 327: 167–170; Barrangou *et al.*, 2007, *Science*, 315: 10 1709-1712; and Makarova *et al.*, 2011, *Nature Reviews Microbiology*, 9: 467-477.

[0078] CRISPR repeats range in size from 24 to 48 base pairs. They usually show some dyad symmetry, implying the formation of a secondary structure such as a hairpin, but are not truly palindromic. CRISPR repeats are separated by spacers of similar length.

[0079] The CRISPR-associated (cas) genes are often associated with CRISPR repeat-spacer arrays. More than forty different Cas protein families have been described (Haft *et al.* 15 2005, *PLoS Comput Biol.* 1 (6): e60). Particular combinations of cas genes and repeat structures have been used to define 8 CRISPR subtypes, some of which are associated with an additional gene module encoding repeat-associated mysterious proteins (RAMPs).

[0080] There are diverse CRISPR systems in different organisms, and one of the 20 simplest is the type II CRISPR system from *Streptococcus pyogenes*: only a single gene encoding the Cas9 protein and two RNAs, a mature CRISPR RNA (crRNA) and a partially complementary trans-acting RNA (tracrRNA), are necessary and sufficient for RNA-guided silencing of foreign DNAs (Gasiunas *et al.*, 2012, *PNAS* 109: E2579-E2586; Jinek *et al.*, 2012, *Science* 337: 816-821). Maturation of crRNA requires tracrRNA and RNase III 25 (Deltcheva *et al.*, 2011, *Nature* 471: 602-607). However, this requirement can be bypassed by using an engineered small guide RNA (sgRNA) containing a designed hairpin that mimics the tracrRNA-crRNA complex (Jinek *et al.*, 2012, *Science* 337: 816-821). Base pairing between the sgRNA and target DNA causes double-strand breaks (DSBs) due to the endonuclease activity of Cas9. Binding specificity is determined by both sgRNA-DNA base 30 pairing and a short DNA motif (protospacer adjacent motif [PAM] sequence: NGG) juxtaposed to the DNA complementary region (Marraffini & Sontheimer, 2010, *Nature Reviews Genetics*, 11: 181-190). For example, the CRISPR system requires a minimal set of two molecules, the Cas9 protein and the sgRNA, and therefore can be used as a host-

- 22 -

independent gene-targeting platform. The Cas9/CRISPR can be harnessed for site-selective RNA-guided genome editing, such as targeting insertion see for example, Carroll, 2012, Molecular Therapy 20: 1658-1660; Chang *et al*, 2013, Cell Research 23: 465-472; Cho *et al*, 2013, Nature Biotechnol 31: 230-232; Cong *et al*, 2013, Science 339: 819-823; Hwang *et al*, 2013, Nature Biotechnol 31: 227-229; Jiang *et al*, 2013, Nature Biotechnol 31: 233-239; Mali *et al*, 2013, Science 339: 823-826; Qi *et al*, 2013, Cell 152: 1173-1183; Shen *et al*, 2013, Cell Research 23: 720-723; and Wang *et al*, 2013, Cell 153: 910-918). In particular, Wang *et al*, 2013, Cell 153: 910-918 describe targeted insertion using the CRISPR/Cas9 system combined with oligonucleotides.

[0081] *TAL (transcription activator-like) Effectors*

[0082] Transcription activator-like (TAL) effectors or TALE (transcription activator-like effector) are derived from a plant pathogenic bacteria genus, *Xanthomonas*, and these proteins mimic plant transcriptional activators and manipulate the plant transcript, see Kay *et al*, 2007, Science, 318:648-651.

[0083] TAL effectors contain a centralized domain of tandem repeats, each repeat containing approximately 34 amino acids, which are key to the DNA binding specificity of these proteins. In addition, they contain a nuclear localization sequence and an acidic transcriptional activation domain, for a review see Schornack *et al* 2006, J. Plant Physiol., 163(3): 256-272; Scholze and Boch, 2011, Curr Opin Microbiol, 14:47-53.

[0084] Specificity of TAL effectors depends on the sequences found in the tandem repeats. The repeated sequence includes approximately 102 bp and the repeats are typically 91-100% homologous with each other (Bonas *et al*, 1989, Mol Gen Genet 218: 127-136). Polymorphism of the repeats is usually located at positions 12 and 13 and there appears to be a one-to-one correspondence between the identity of the hypervariable diresidues at positions 12 and 13 with the identity of the contiguous nucleotides in the TAL-effector's target sequence, see Moscou and Bogdanove 2009, Science 326: 1501; and Boch *et al*, 2009, Science 326:1509-1512. The two hypervariable residues are known as repeat variable diresidues (RVDs), whereby one RVD recognizes one nucleotide of DNA sequence and ensures that the DNA binding domain of each TAL-effector can target large recognition sites with high precision (15 - 30nt). Experimentally, the code for DNA recognition of these TAL-effectors has been determined such that an HD sequence at positions 12 and 13 leads to a binding to cytosine (C), NG binds to T, NI to A, C, G or T, NN binds to A or G, and IG binds to T. These DNA binding repeats have been assembled into proteins with new combinations

- 23 -

and numbers of repeats, to make artificial transcription factors that are able to interact with new sequences and activate the expression of a reporter gene in plant cells (Boch *et al.* 2009, Science 326:1509-1512). These DNA binding domains have been shown to have general applicability in the field of targeted genomic editing or targeted gene regulation in all cell types, see Gaj *et al.*, Trends in Biotechnol, 2013, 31(7):397-405. Moreover, engineered TAL effectors have been shown to function in association with exogenous functional protein effector domains such as a nuclease, not naturally found in natural *Xanthomonas* TAL-effect or proteins in mammalian cells. TAL nucleases (TALNs or TALENs) can be constructed by combining TALs with a nuclease, e.g. FokI nuclease domain at the N-terminus or C-terminus, Kim *et al.* 1996, PNAS 93:1156-1160; Christian *et al.* 2010, Genetics 186:757-761; Li *et al.*, 2011, Nucleic Acids Res 39: 6315-6325; and Miller *et al.*, 2011, Nat Biotechnol 29: 143-148. The functionality of TALENs to cause deletions by NHEJ has been shown in rat, mouse, zebrafish, *Xenopus*, medaka, rat and human cells, Ansai *et al.*, 2013, Genetics, 193: 739-749; Carlson *et al.*, 2012, PNAS, 109: 17382-17387; Hockemeyer *et al.*, 2011, Nature Biotechnol., 29: 731-734; Lei *et al.*, 2012, PNAS, 109: 17484-17489; Moore *et al.*, 2012, PLoS ONE, 7: e37877; Stroud *et al.*, 2013, J. Biol. Chem., 288: 1685-1690; Sung *et al.*, 2013, Nature Biotechnol 31: 23-24; Wefers *et al.*, 2013, PNAS 110: 3782-3787.

[0085] For TALEN, methods of making such are further described in the US Pat. Nos. 8,420,782, 8,450,471, 8,450,107, 8,440,432 and 8,440,431, and US patent application publications 2013/0137161 and 2013/0137174.

[0086] Other useful endonucleases may include, for example, HhaI, HindIII, NotI, BbvCI, EcoRI, BglI, and AlwI. The fact that some endonucleases (e.g., FokI) only function as dimers can be capitalized upon to enhance the target specificity of the TAL effector. For example, in some cases each FokI monomer can be fused to a TAL effector sequence that recognizes a different DNA target sequence, and only when the two recognition sites are in close proximity do the inactive monomers come together to create a functional enzyme. By requiring DNA binding to activate the nuclease, a highly site-specific restriction enzyme can be created.

[0087] In some embodiments, the TALEN may further include a nuclear localization signal or sequence (NLS). A NLS is an amino acid sequence that facilitates targeting the TALEN nuclease protein into the nucleus to introduce a double stranded break at the target sequence in the chromosome.

- 24 -

[0088] Nuclear localization signals are known in the art, see, for example, Makkerh *et al.* 1996, *Curr Biol.* 6:1025-1027. NLS include the sequence PKKKRKV (SEQ ID NO:16) from SV40 Large T-antigen, Kalderon 1984, *Cell*, 39: 499-509; RPAATKKAGQAKKK (SEQ ID NO:17) from nucleoplasmin, Dingwall *et al.*, 1988, *J Cell Biol.*, 107, 841-9. Further examples are described in McLane and Corbett 2009, *IUBMB Life*, 61, 697-70; Dopie *et al.* 2012, *PNAS*, 109, E544-E552.

[0089] The cleavage domain may be obtained from any endonuclease or exonuclease. Non-limiting examples of endonucleases from which a cleavage domain may be derived include, but are not limited to, restriction endonucleases and homing endonucleases. See, for example, 2002-2003 Catalog, New England Biolabs, Beverly, Mass.; and Belfort *et al.* (1997) *Nucleic Acids Res.* 25:3379-3388. Additional enzymes that cleave DNA are known, e.g., SI Nuclease; mung bean nuclease; pancreatic DNase I; micrococcal nuclease; yeast HO endonuclease. See also Linn *et al.* (eds.) *Nucleases*, Cold Spring Harbor Laboratory Press, 1993. One or more of these enzymes, or functional fragments thereof, may be used as a source of cleavage domains.

[0090] Zinc Finger-Mediated Genome Editing

[0091] The use of zinc finger nucleases (ZFN) for gene editing, such as for targeted insertion via a homology-directed repair process, has been well established. For example, see Carbery *et al.*, 2010, *Genetics*, 186: 451-459; Cui *et al.*, 2011, *Nature Biotechnol.*, 29: 64-68; Hauschild *et al.*, 2011, *PNAS*, 108: 12013-12017; Orlando *et al.*, 2010, *Nucleic Acids Res.*, 38: e152-e152; and Porteus & Carroll, 2005, *Nature Biotechnology*, 23: 967-973.

[0092] Components of the ZFN-mediated process include a zinc finger nuclease with a DNA binding domain and a cleavage domain. Such are described for example in Beerli *et al.* (2002) *Nature Biotechnol.*, 20:135-141; Pabo *et al.* (2001) *Ann. Rev. Biochem.*, 70:313-340; Isalan *et al.* (2001) *Nature Biotechnol.* 19:656-660; Segal *et al.* (2001) *Curr Opin. Biotechnol.*, 12:632-637; and Choo *et al.* (2000) *Curr Opin. Struct. Biol.*, 10:411-416; and U.S. Pat. Nos. 6,453,242 and 6,534,261. Methods to design and select a zinc finger binding domain to a target sequence are known in the art, see for example Sera, *et al.*, *Biochemistry* 2002,41,7074-7081; U.S. Pat. Nos. 6,607,882; 6,534,261 and 6,453,242.

[0093] In some embodiments, the zinc finger nuclease may further include a nuclear localization signal or sequence (NLS). A NLS is an amino acid sequence that facilitates targeting the zinc finger nuclease protein into the nucleus to introduce a double stranded

- 25 -

break at the target sequence in the chromosome. Nuclear localization signals are known in the art. See, for example, Makkerh *et al.* (1996) *Current Biology* 6:1025-1027.

[0094] The cleavage domain may be obtained from any endonuclease or exonuclease. Non-limiting examples of endonucleases from which a cleavage domain may be derived include, but are not limited to, restriction endonucleases and homing endonucleases. See, for example, 2002-2003 Catalog, New England Biolabs, Beverly, Mass.; and Belfort *et al.* (1997) *Nucleic Acids Res.* 25:3379-3388. Additional enzymes that cleave DNA are known (e.g., SI Nuclease; mung bean nuclease; pancreatic DNase I; micrococcal nuclease; yeast HO endonuclease). See also Linn *et al.* (eds.) *Nucleases*, Cold Spring Harbor Laboratory Press, 1993. One or more of these enzymes (or functional fragments thereof) may be used as a source of cleavage domains. A cleavage domain also may be derived from an enzyme or portion thereof, as described above, that requires dimerization for cleavage activity.

[0095] Two zinc finger nucleases may be required for cleavage, as each nuclease includes a monomer of the active enzyme dimer. Alternatively, a single zinc finger nuclease may include both monomers to create an active enzyme dimer. Restriction endonucleases (restriction enzymes) are present in many species and are capable of sequence-specific binding to DNA (at a recognition site), and cleaving DNA at or near the site of binding. Certain restriction enzymes (e.g., Type IIS) cleave DNA at sites removed from the recognition site and have separable binding and cleavage domains. For example, the Type IIS enzyme FokI catalyzes double stranded cleavage of DNA, at 9 nucleotides from its recognition site on one strand and 13 nucleotides from its recognition site on the other. See, for example, U.S. Pat. Nos. 5,356,802; 5,436,150 and 5,487,994; as well as Li *et al.* (1992) *PNAS* 89:4275-4279; Li *et al.* (1993) *PNAS* 90:2764-2768; Kim *et al.* (1994) *PNAS* 91:883-887; Kim *et al.* (1994) *J. Biol. Chem.* 269:31, 978-31, 982. Thus, a zinc finger nuclease may include the cleavage domain from at least one Type IIS restriction enzyme and one or more zinc finger binding domains, which may or may not be engineered. Exemplary Type IIS restriction enzymes are described for example in International Publication WO 07/014275, the disclosure of which is incorporated by reference herein in its entirety. Additional restriction enzymes also contain separable binding and cleavage domains, and these also are contemplated by the present disclosure. See, for example, Roberts *et al.* (2003) *Nucleic Acids Res.* 31: 418-420. An exemplary Type IIS restriction enzyme, whose cleavage domain is separable from the binding domain, is FokI. This particular enzyme is active as a dimer (Bitinaite *et al.* 1998, *PNAS* 95: 10,570-10,575). Accordingly, for the purposes of the present

- 26 -

disclosure, the portion of the FokI enzyme used in a zinc finger nuclease is considered a cleavage monomer. Thus, for targeted double stranded cleavage using a FokI cleavage domain, two zinc finger nucleases, each including a FokI cleavage monomer, may be used to reconstitute an active enzyme dimer. Alternatively, a single polypeptide molecule containing a zinc finger binding domain and two FokI cleavage monomers may also be used. In certain embodiments, the cleavage domain may include one or more engineered cleavage monomers that minimize or prevent homodimerization, as described, for example, in U.S. Patent Publication Nos. 2005/0064474, 2006/0188987, and 2008/0131962, each of which is incorporated by reference herein in its entirety. By way of non-limiting example, amino acid residues at positions 446, 447, 479, 483, 484, 486, 487, 490, 491, 496, 498, 499, 500, 531, 534, 537 and 538 of FokI are all targets for influencing dimerization of the FokI cleavage half-domains. Exemplary engineered cleavage monomers of FokI that form obligate heterodimers include a pair in which a first cleavage monomer includes mutations at amino acid residue positions 490 and 538 of FokI and a second cleavage monomer that includes mutations at amino-acid residue positions 486 and 499. Thus, in one embodiment, a mutation at amino acid position 490 replaces Glu (E) with Lys (K); a mutation at amino acid residue 538 replaces Ile (I) with Lys (K); a mutation at amino acid residue 486 replaces Gln (Q) with Glu (E); and a mutation at position 499 replaces Ile (I) with Lys (K). Specifically, the engineered cleavage monomers may be prepared by mutating positions 490 from E to K and 538 from I to K in one cleavage monomer to produce an engineered cleavage monomer designated "E490K:I538K" and by mutating positions 486 from Q to E and 499 from I to L in another cleavage monomer to produce an engineered cleavage monomer designated "Q486E:I499L." The above described engineered cleavage monomers are obligate heterodimer mutants in which aberrant cleavage is minimized or abolished. Engineered cleavage monomers may be prepared using a suitable method, for example, by site-directed mutagenesis of wild-type cleavage monomers (FokI) as described in U.S. Patent Publication No. 2005/0064474.

[0096] The zinc finger nuclease described above may be engineered to introduce a double stranded break at the targeted site of integration. The double stranded break may be at the targeted site of integration, or it may be up to 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100 or 1000 nucleotides away from the site of integration. In some embodiments, the double stranded break may be up to 1, 2, 3, 4, 5, 10, 15, or 20 nucleotides away from the site of integration. In other embodiments, the double stranded break may be up to 10, 15, 20, 25,

- 27 -

30, 35, 40, 45 or 50 nucleotides away from the site of integration. In yet other embodiments, the double stranded break may be up to 50, 100 or 1000 nucleotides away from the site of integration.

[0097] The DRAP technology has been described in US Pat. Nos. 6,534,643, 6,858,716 and 6,830,910 and Watt *et al.*, 2006.

[0098] Optionally, a nucleic acid sequence encoding a protein can be inserted at a random target site in the genome so that the genome includes a nucleic acid encoding the protein. Typically, for random insertion, the nucleic acid sequence also contains a promoter to drive expression of the inserted nucleic acid.

[0099] In a further option, a nucleic acid encoding the desired protein, APOE4p, Trem2p or both APOE4p and Trem2p, is inserted into a predetermined target site in the genome other than the Apoe4 gene or the Trem2 gene.

[00100] For example, a nucleic acid encoding the desired protein, APOE4p, Trem2p or both APOE4p and Trem2p, is inserted into a predetermined target site in the genome known to result in reliable expression, such as the Hprt or the Rosa26 locus.

[00101] According to aspects, for genomic editing at a predetermined target site, a targeting construct is made using recombinant DNA techniques and includes 5' and 3' sequences which are homologous to the targeted endogenous gene in the cell. The targeting construct further includes a selectable marker such as neomycin phosphotransferase, hygromycin or puromycin, a nucleic acid encoding the desired protein, APOE4p, Trem2p or both APOE4p and Trem2p, and optionally a polyadenylation signal. To insure correct transcription and translation of the nucleic acid encoding the desired protein, the nucleic acid encoding the desired protein is either in frame with the endogenous gene locus, or a splice acceptor site and internal ribosome entry site (IRES) sequences can be included.

[00102] Such a targeting construct is transfected into a desired cell type, such as but not limited to, stem cells and the cells are screened to detect the correct genomic editing event using PCR, Southern blot or sequencing analysis. Cells with the correct genomic editing event can be further analyzed for expression of the encoded protein by protein analysis, such as ELISA or Western blot analysis. If desired, the nucleic acid encoding the selectable marker can be configured to be removed by treating the stem cells with a recombinase such as Cre recombinase or Flippase (Flp). After recombinase treatment, the cells are analyzed for the presence of the nucleic acid encoding the desired protein.

- 28 -

[00103] Cells with the correct genomic editing event are selected and injected into preimplantation embryos as described above. Chimeric males are selected for breeding. Offspring can be analyzed for transmission of the ES cell genome by coat color and genetic analysis, such as PCR, Southern blot or sequencing and can be tested for expression of the
5 desired protein, such as by protein analysis (Western blot, ELISA) or other functional assays. Offspring expressing the correct proteins are intercrossed to create mice homozygous for the genetic modification(s).

[00104] Generation of a genetically modified mouse expressing APOE4p and Trem2p may include injection or transfection of appropriate nucleic acids, such as one or more one or
10 more nucleic acids encoding a desired protein and/or one or more expression constructs, such as an expression construct encoding a protein or RNA (such as cas9 or a guide RNA for use in CRISPR), into a preimplantation embryo or stem cells, such as embryonic stem (ES) cells or induced pluripotent stem (iPS) cells.

[00105] The terms "expression construct" and "expression cassette" are used herein to
15 refer to a double-stranded recombinant DNA molecule containing a desired nucleic acid coding sequence and containing one or more regulatory elements necessary or desirable for the expression of the operably linked coding sequence.

[00106] The term "regulatory element" as used herein refers to a nucleotide sequence which controls some aspect of the expression of nucleic acid sequences. Exemplary
20 regulatory elements illustratively include an enhancer, an internal ribosome entry site (IRES), an intron; an origin of replication, a polyadenylation signal (pA), a promoter, a transcription termination sequence, and an upstream regulatory domain, which contribute to the replication, transcription, post-transcriptional processing of a nucleic acid sequence. Those of ordinary skill in the art are capable of selecting and using these and other regulatory
25 elements in an expression construct with no more than routine experimentation. Expression constructs can be generated recombinantly or synthetically using well-known methodology.

[00107] The term "operably linked" as used herein refers to a nucleic acid in functional relationship with a second nucleic acid.

[00108] A regulatory element is included in an expression cassette is a promoter in
30 particular embodiments. The term "promoter" as used herein refers to a DNA sequence operably linked to a nucleic acid sequence to be transcribed such as a nucleic acid sequence encoding a desired molecule. A promoter is generally positioned upstream of a nucleic acid sequence to be transcribed and provides a site for specific binding by RNA polymerase and

- 29 -

other transcription factors. In specific embodiments, a promoter is generally positioned upstream of the nucleic acid sequence transcribed to produce the desired molecule, and provides a site for specific binding by RNA polymerase and other transcription factors. An included promoter can be a constitutive promoter or can provide inducible expression; and can provide ubiquitous, tissue-specific or cell-type specific expression.

[00109] Ubiquitous promoters that can be included in an expression construct include, but are not limited to, a 3-phosphoglycerate kinase (PGK-1) promoter, a beta-actin promoter, a ROSA26 promoter, a heat shock protein 70 (Hsp70) promoter, an EF-1 alpha gene encoding elongation factor 1 alpha (EF1) promoter, an eukaryotic initiation factor 4A (eIF-4A1) promoter, a chloramphenicol acetyltransferase (CAT) promoter and a CMV (cytomegalovirus) promoter.

[00110] These and other promoters are known in the art as exemplified in Abboud, S. L. et al, J. Histochem & Cytochem., 51(7):941-949, 2003; Schorpp *et al.*, Nucl. Acids Res., 24(9):1787-1788, 1996; McBurney, M. W. *et al.*, Devel. Dynamics, 200:278-293, 1994; and Majumder, M. *et al.*, Blood, 87(8):3203-3211, 1996.

[00111] In addition to a promoter, one or more enhancer sequences may be included such as, but not limited to, cytomegalovirus (CMV) early enhancer element and an SV40 enhancer element.

[00112] Additional included sequences include an intron sequence such as the beta globin intron or a generic intron, a transcription termination sequence, and an mRNA polyadenylation (pA) sequence such as, but not limited to SV40-pA, beta-globin-pA and SCF-pA.

[00113] An expression construct may include sequences necessary for amplification in bacterial cells, such as a selection marker (e.g. kanamycin or ampicillin resistance gene) and a replicon.

[00114] For methods of DNA injection of an expression construct into a preimplantation embryo, the expression construct is optionally linearized before injection into mouse preimplantation embryos. Preferably the expression construct is injected into fertilized oocytes. Fertilized oocytes are collected from superovulated females the day after mating (0.5 dpc) and injected with the expression construct. The injected oocytes are either cultured overnight or transferred directly into oviducts of 0.5-day p.c. pseudopregnant females.

[00115] Methods for superovulation, harvesting of oocytes, expression construct injection and embryo transfer are known in the art and described in Manipulating the Mouse Embryo:

- 30 -

A Laboratory Manual, 3rd edition, Cold Spring Harbor Laboratory Press; December 15, 2002, ISBN-10: 0879695919.

[00116] Offspring can be tested for the presence of the desired mutation or inserted sequence by DNA analysis, such as PCR, Southern blot or sequencing. Mice which are carrying the desired mutation or inserted sequence can be tested for protein expression such as for example, by ELISA or Western blot analysis.

[00117] Alternatively, a nucleic acid or expression construct may be transfected into stem cells (ES cells or iPS cells) using well-known methods, such as electroporation, calcium-phosphate precipitation and lipofection. The cells are screened for the presence of the desired mutation or inserted sequence by DNA analysis, such as PCR, Southern blot or sequencing. Cells with the desired mutation or inserted sequence by can be tested for functional expression by protein analysis, such as for example, by ELISA or Western blot analysis.

[00118] Mouse ES cells are grown in media optimized for the particular line. Typically ES media contains 15% fetal bovine serum (FBS) or synthetic or semi-synthetic equivalents, 2 mM glutamine, 1 mM Na pyruvate, 0.1 mM non-essential amino acids, 50 U/ml penicillin and streptomycin, 0.1 mM 2-mercaptoethanol and 1000 U/ml LIF (plus, for some cell lines chemical inhibitors of differentiation) in Dulbecco's Modified Eagle Media (DMEM). A detailed description is known in the art (Tremml et al., 2008, Current Protocols in Stem Cell Biology, Chapter 1:Unit 1C.4. For review of inhibitors of ES cell differentiation, see Buehr, M.,et al. (2003). Genesis of embryonic stem cells. Philosophical Transactions of the Royal Society B: Biological Sciences 358, 1397-1402.

[00119] Selected cells incorporating the desired mutation or inserted sequence can be injected into preimplantation embryos. For microinjection, ES or iPS cell are rendered to single cells using a mixture of trypsin and EDTA, followed by resuspension in ES media. Groups of single cells are selected using a finely drawn-out glass needle (20-25 micrometer inside diameter) and introduced through the embryo's zona pellucida and into the blastocysts cavity (blastocoel) using an inverted microscope fitted with micromanipulators.

[00120] Alternatively, to blastocyst injection, stem cells can be injected into early stage embryos (e.g. 2-cell, 4-cell, 8-cell, premorula or morula). Injection may be assisted with a laser or piezo pulses drilled opening the zona pellucida. Approximately 9-10 selected stem cells (ES or iPS cells) are injected per blastocysts, or 8-cell stage embryo, 6-9 stem cells per 4-cell stage embryo, and about 6 stem cells per 2-cell stage embryo. Following stem cell introduction, embryos are allowed to recover for a few hours at 37 °C in 5% CO₂, 5% O₂ in

- 31 -

nitrogen or cultured overnight before transfer into pseudopregnant recipient females. In a further alternative to stem cell injection, stem cells can be aggregated with morula stage embryos. All these methods are well established and can be used to produce stem cell chimeras. For a more detailed description see *Manipulating the Mouse Embryo: A Laboratory Manual*, 3rd edition (A. Nagy, M. Gertsenstein, K. Vintersten, R. Behringer, Cold Spring Harbor Laboratory Press; December 15, 2002, ISBN-10: 0879695919, Nagy *et al.*, 1990, Development 110, 815-821; US 7,576,259; Method for making genetic modifications, US7659442, US 7,294,754, and Kraus *et al.* 2010, Genesis 48, 394-399.

[00121] Pseudopregnant embryo recipients are prepared using methods known in the art.

Briefly, fertile female mice between 6-8 weeks of age are mated with vasectomized or sterile males to induce a hormonal state conducive to supporting surgically introduced embryos. At 2.5 days post coitum (dpc) up to 15 of the stem cell containing blastocysts are introduced into the uterine horn very near to the uterus-oviduct junction. For early stage embryos and morula, such embryos are either cultured in vitro into blastocysts or implanted into 0.5 dpc or 1.5 dpc pseudopregnant females according to the embryo stage into the oviduct. Chimeric pups from the implanted embryos are born 16-20 days after the transfer depending on the embryo age at implantation. Chimeric males are selected for breeding. Offspring can be analyzed for transmission of the ES cell genome by coat color and genetic analysis, such as PCR, Southern blot or sequencing. Further the expression of the encoded protein(s) can be analyzed by protein analysis (Western blot, ELISA) or other functional assays.

[00122] A genetically modified mouse of the present invention may be heterozygous or homozygous for the genetic modification.

[00123] According to aspects of the present invention, a genetically modified mouse of the present invention may be heterozygous or homozygous for the "knock-in" humanized APOE4 modification wherein the mouse expresses APOE4p and also may be heterozygous or homozygous for the mutated genomic sequence encoding Trem2p wherein the mouse expresses Trem2p.

[00124] Homozygous genetically modified mice expressing APOE4p can be crossed with homozygous genetically modified mice expressing Trem2p to create a congenic strain homozygous for both modifications and expressing both APOE4p and Trem2p according to embodiments.

[00125] Genetically modified mice of the present invention can be any of various strains.

[00126] A genetic modification can be introduced into the genome of an isolated mouse embryonic stem (ES) cell, a mouse induced pluripotent stem (iPS) cell, a mouse somatic cell, a fertilized mouse oocyte (zygote) or a mouse embryo in a knock-in strategy to produce a genetically modified mouse of the present invention.

5 [00127] Embodiments of the invention provide a genetically modified mouse that includes a desired genetic modification in all or substantially all of its cells, as well as a genetically modified mouse that includes a desired genetic modification in some, but not all its cells.

[00128] A genetically modified mouse according to aspects of the present invention can
10 include one or more additional genetic variants associated with increased risk of late-onset Alzheimer disease in humans.

[00129] Identification of Treatments and Compounds

[00130] Methods for screening for putative treatments for human Alzheimer's disease are provided according to embodiments of the present invention which include: administering a
15 putative treatment for Alzheimer's disease to a genetically modified mouse, wherein the genome of the mouse includes: 1) a DNA sequence encoding human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding mouse Trem2 protein having a mutation p.R47H (Trem2p) operably linked to a promoter, wherein the mouse expresses APOE4p and Trem2p and wherein the mouse is characterized by one or
20 more symptoms or signs associated with expression of APOE4p and Trem2p relevant to non-familial late-onset Alzheimer's disease of the present invention; and assessing an effect of the putative treatment on the mouse.

[00131] Methods for screening for putative treatments for human Alzheimer's disease are provided according to embodiments of the present invention which include: administering a
25 putative treatment for Alzheimer's disease to a B6(SJL)-*ApoE^{tm1.1(APOE*4)Aduj} Trem2^{em1Aduj}/J* mouse whose genome includes: 1) a DNA sequence encoding human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding mouse Trem2 protein having a mutation p.R47H (Trem2p) operably linked to a promoter, wherein the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence
30 encoding Trem2p, and wherein the mouse expresses human APOE4p and mouse Trem2p; and assessing an effect of the putative treatment on the mouse.

[00132] Methods for screening for a compound for use in the treatment of Alzheimer's disease, are provided according to aspects of the present invention which include

- 33 -

administering a compound to a genetically modified mouse of the present invention; and assessing an effect of the compound in the treatment of one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease. Assessing an effect of the compound in the treatment of one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease preferably includes comparing the result of the assessment with a suitable control, such as, but not limited to, the effect of the compound on a control, such as an APOE3-expressing mouse or a wild-type mouse (e.g. a mouse carrying the *ApoE* gene).

[00133] Such signs and symptoms include, but are not limited to, any one or more of: 1) presence of significantly more microglia in the brain of a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse; 2) presence of significantly more amyloid plaques in the brain of a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse; 3) presence of significantly more tau aggregates in the brain of a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse; 4) presence of significantly more inflammation in the brain of a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse; 5) presence of significantly more synaptic and/or neuronal loss in the brain of a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse; 6) presence of significantly more cognitive deficit in the brain of a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse; 7) presence of significantly more indications of frailty in an aging genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse; 8) presence of significantly more blood flow deficit in the brain of a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse; 9) a significant difference in presence, level, and/or function of one or more biomarkers of non-familial late-onset Alzheimer's disease in blood, serum, or tissue of a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse; 10) cerebrovascular leakage in a genetically modified mouse of the present invention compared

- 34 -

to a control, such as an APOE3-expressing mouse or wild-type control mouse; and 11) levels of one or more blood lipoproteins, such as high density lipoprotein, and low density lipoprotein, and/or cholesterol, in a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse.

5 [00134] According to aspects of the present invention, methods for screening for putative treatments for human Alzheimer's disease are provided wherein assessing an effect of a compound includes comparing the effect of the compound on the genetically modified mouse, wherein the genome of the mouse includes: 1) a DNA sequence encoding human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding
10 mouse Trem2 protein having a mutation p.R47H (Trem2p) operably linked to a promoter, wherein the mouse expresses APOE4p and Trem2p and wherein the mouse is characterized by one or more symptoms or signs associated with expression of APOE4p and Trem2p relevant to non-familial late-onset Alzheimer's disease of the present invention, with a control.

15 [00135] According to aspects of the present invention, methods for screening for putative treatments for human Alzheimer's disease are provided wherein assessing an effect of the compound includes comparing the effect of the compound on a B6(SJL)-*ApoE^{tm1.1(APOE*4)Aduj}*
Trem2^{em1Aduj}/J mouse with a control.

[00136] A suitable control includes, for example, administering the compound to a
20 mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the compound on the mouse. A suitable control includes, for example, administering the compound to an APOE3-expressing mouse or wild-type control mouse. A wild-type control mouse can be any mouse which does not express human APOE4p and mouse Trem2p. A suitable control includes, for example, administering the compound to a wild-type C57BL/6J
25 mouse; and assessing an effect of the compound on the wild-type C57BL/6J mouse.

[00137] Symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease can be assessed by methods well-known in the art including, but not limited to, immunoassay, nucleic acid assay, histochemical staining, cognitive assays, *in vivo* imaging, physical assessment of the animals,
30 cerebrovascular leakage assessment, and morphological assessment of tissues and/or cells.

[00138] Immunoassays that can be used are well-known in the art and include, but are not limited to, enzyme-linked immunosorbent assay (ELISA) such as but not limited to, antigen capture ELISA, indirect ELISA, fixed cell ELISA; immunochromatography; antigen capture;

- 35 -

flow cytometry; immunoblot; immunoprecipitation; immunodiffusion; competitive immunoassays, immunocytochemistry; radioimmunoassay; and combinations of any of these. Generalized details of immunoassays are described in standard references, illustratively including Wild, D., The Immunoassay Handbook, 3rd Ed., Elsevier Science, 2005; Gosling, J. P., Immunoassays: A Practical Approach, Practical Approach Series, Oxford University Press, 2005; E. Harlow and D. Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1988; F. Breitling and S. Dübel, Recombinant Antibodies, John Wiley & Sons, New York, 1999; H. Zola, Monoclonal Antibodies: Preparation and Use of Monoclonal Antibodies and Engineered Antibody Derivatives, Basics: From Background to Bench, BIOS Scientific Publishers, 2000; B.K.C. Lo, Antibody Engineering: Methods and Protocols, Methods in Molecular Biology, Humana Press, 2003; F. M. Ausubel et al., Eds., Short Protocols in Molecular Biology, Current Protocols, Wiley, 2002; Ormerod, M. G., Flow Cytometry: a practical approach, Oxford University Press, 2000; and Givan, A. L., Flow Cytometry: first principles, Wiley, New York, 2001.

[00139] According to aspects of the present invention, nucleic acid assays to detect a nucleic acid analyte relevant to non-familial late-onset Alzheimer's disease in a genetically modified mouse of the present invention compared to a wild-type mouse includes, but is not limited to, nucleic acid amplification techniques such as, but not limited to, PCR, RT-PCR ligation-mediated PCR and phi-29 PCR; nucleic acid hybridization techniques such as, but not limited to, Northern blot, Southern blot, RNase protection assay, dot blot, transcriptome analysis, and *in situ* hybridization. Nucleic acid assays for both qualitative and quantitative assay of a nucleic acid in a sample are described in detail in standard references, illustratively including J. Sambrook and D.W. Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press; 3rd Ed., 2001; F. M. Ausubel et al., Eds., Short Protocols in Molecular Biology, Current Protocols, Wiley, 2002; C.W. Dieffenbach et al., PCR Primer: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 2003; and V. Demidov et al., DNA Amplification: Current Technologies and Applications, Taylor & Francis, 2004.

[00140] Biomarker assays that can be used are well-known in the art and include, but are not limited to, assays of A β and tau species, neurofilaments, neurogranin, interleukins, TNF α , GM-CSF, and soluble Trem2 in cerebrospinal fluid (CSF), blood, serum, or tissue.

[00141] Cognitive assays that can be used are well-known in the art and include, but are not limited to, assays of spatial memory, short-term memory, long-term memory, assays of executive function, attentional tasks such as 3 and 5 choice serial reaction time tests, tests of

- 36 -

processing speed, set shifting tests, reversal learning tasks, assays of object memory, assays of pattern recognition, assays of passive avoidance memory, assays of habituation, and assays of novel object recognition, water maze testing, fear conditioning tests, radial arm water maze testing, Y-maze testing, T-maze testing, and open field habituation tests.

5 [00142] Physical assessment methods of the animals that can be used are well-known in the art and include, but are not limited to, assessment of indices of frailty in a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or a wild-type mouse as a comparison to normal aging.

10 [00143] *In vivo* imaging methods that can be used are well-known in the art and include, but are not limited to, magnetic resonance imaging (MRI), computed tomography (CT) imaging, X-ray, optical imaging, and ultrasound imaging. Such imaging techniques can be used to assess one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease including, but not limited to, amyloid or tau aggregation, abnormal blood flow, pathological neuronal loss, and
15 abnormal glucose metabolism.

[00144] Assessment of changes to one or more of: a transcriptomic profile, a proteomic profile, and a metabolic profile of a genetically modified mouse of the present invention compared to a wild-type mouse and/or compared to clinical samples can be performed using methods that are well-known in the art.

20 [00145] Assessment of inflammation can be performed by assay of one or more biomarkers of inflammation, such as, but not limited to, IL-8, IL-11, TNF-alpha, granulocyte-macrophage colony stimulating factor (GM-CSF), TGF-beta, VEGF, monocyte chemotactic factor-1, macrophage migratory inhibitory factor, s100B, fibrinogen, and interferon gamma-inducible protein 10. Such assays can be performed on samples obtained from a genetically
25 modified mouse of the present invention and a wild-type mouse, such as a sample of brain, spinal cord, blood, plasma, serum, cerebrospinal fluid or other relevant tissue or body fluid.

[00146] Morphological assessment of tissues and/or cells can include physical examination of gross anatomy and/or microscopic examination of tissues and/or cells with or without histochemical or cytochemical staining of the tissues and/or cells. Morphological
30 assessment of tissues and/or cells can include assessment of synaptic and neuronal loss.

[00147] A method for screening for a compound for use in the treatment of Alzheimer's disease in an individual human subject having or suspected of having Alzheimer's disease is provided according to aspects of the present invention which include administering a

- 37 -

compound to a genetically modified mouse of the present invention; and assessing an effect of the compound on amyloid and/or tau which are associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to particular embodiments, assessing an effect of the compound on amyloid and/or tau includes assessing the level and/or localization of amyloid and/or tau. According to particular embodiments, assessing an effect of the compound on amyloid and/or tau includes assessing amyloid and/or tau aggregates in a genetically modified mouse of the present invention, such as assessment of aggregate size, number, location or a combination of any two or more thereof.

[00148] Cerebrovascular leakage is a key aspect of non-familial late-onset Alzheimer's disease and it is a surprising and unexpected finding of the present invention that expression of human APOE4p and mouse Trem2p results in cerebrovascular leakage.

[00149] A method for screening for a compound for use in the treatment of non-familial late-onset Alzheimer's disease in an individual human subject having or suspected of having non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention which include administering a compound to a genetically modified mouse of the present invention; and assessing an effect of the compound on cerebrovascular leakage which is associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease in the mouse. Assessing an effect of the compound on cerebrovascular leakage includes, but is not limited to, assessment of cerebrovascular permeability. The term "cerebrovascular permeability" refers to the capacity of a blood vessel wall to allow for normal movement of small molecules or substances such as water, ions, certain drugs and nutrients across the blood vessel wall while acting as a barrier to movement of larger molecules and substances, such as fibrinogen, and albumin. The term "cerebrovascular leakage" refers to an abnormality of blood vessels which results in leakage of larger molecules and substances, such as fibrinogen, and albumin, through blood vessel walls. Assays for assessing cerebrovascular leakage are well-known in the art, including *in vitro* assays using cells or tissues isolated from a genetically modified mouse of the present invention, and *in vivo* assays. A non-limiting example of an *in vivo* assay of cerebrovascular leakage includes intravenous injection of a labeled protein (e.g. Evans Blue-labeled albumin) and assessment of appearance of the dye-labeled protein in brain tissues, see for example, Radu et al., An *in vivo* Assay to Test Blood Vessel Permeability., J. Vis. Exp. 2013, (73):50062.

- 38 -

[00150] The putative treatment can be any treatment modality such as, but not limited to, administration of a compound. The term "compound" as used herein is not limited and encompasses small molecule chemicals and biologicals such as peptides, proteins, glycoproteins, including antibodies, for example.

5 [00151] Embodiments of inventive compositions and methods are illustrated in the following examples. These examples are provided for illustrative purposes and are not considered limitations on the scope of inventive compositions and methods.

[00152] Examples

[00153] Generation of a Genetically Modified Mouse Having a DNA Sequence

10 Encoding APOE4p in Its Genome

[00154] The mouse Apoe4 gene is located on chromosome 7 at 19,696,109 – 19,699,166. An APOE4 gene-targeting construct was made that included 4980 bp (SEQ ID NO:9) of mouse sequence, which defined the mouse 5' homology arm including exon 1 of mouse ApoE, 4292 bp (SEQ ID NO:10) of human APOE4 sequence including human protein coding
15 exons 2-4 of the human gene as well as an additional 1.5 kb of flanking human sequence after the 3'UTR to include any potential regulatory sequences.

[00155] Figure 1 shows a schematic diagram of the humanized ApoE4 construct (see "m/hAPOE targeting vector E4"). On Figure 1, (C C) above exon 4' shows the nt present in exon 4 for arginine at p.R310 and R176, respectively, isoform E4. Isoform E2 with (T T)
20 codes for cysteine at both C130 and C176, while E3 (T C) codes for cysteine at C130R and arginine at R176 sites.

[00156] Human APOE4 exon 4 contains sequence that codes for the ApoE4 isoform of the gene and encodes the nucleotide sequence for arginine at R130 and R176. It is noted that APOE4 includes an 18 amino acid signal peptide at the N-terminus of the protein such that
25 APOE4 including the signal peptide is 317 amino acids and the variant amino acids which differ among APOE2, APOE3 and APOE4 are at positions 130 and 176. In the mature APOE proteins (299 amino acids), the variant amino acids which differ among APOE2, APOE3 and APOE4 are at positions 112 and 158.

[00157] A Frt neo Frt selection cassette (FNF cassette, SEQ ID NO:11) was inserted after
30 the human sequence followed by a Nde1 restriction site (for ease of Southern screening). The FNF cassette is followed by 5166 bp of mouse sequence (SEQ ID NO:12), the 3' homology arm. The resulting 14,438 bp synthesized construct was cloned into pBlight vector using

- 39 -

recombineering techniques, producing a construct called mApoE_hAPOE4_PGKneo_mAPOE for gene targeting in embryonic stem cells.

[00158] The ApoE4 gene-targeting construct was introduced into cultured embryonic stem (ES) cells of a C57Bl6 mouse strain by electroporation. Homologous recombination produced loci that retained all normal mouse regulatory sequences (plus non-coding exon one) together with the human APOE4 protein-encoding exons 2-4. Transfected ES cells were screened by Southern blot to ensure correct targeting. Three clones were identified that were correctly targeted. ES cells containing the correctly targeted locus were introduced into C57BL/6J embryos, and the resultant chimeric mice were bred with C57BL/6J mice. Offspring carrying the modified locus in the germ-line were interbred to generate the homozygous genetically modified genome. All F1 matings produced normal litter sizes with a Mendelian distribution of the locus.

[00159] Generation of a Genetically Modified Mouse Having a DNA Sequence Encoding Trem2p in Its Genome

[00160] The Trem2 R47H KI allele was generated at The Jackson Laboratory by pronuclear injection of Cas9 RNA (100 ng) and a single guide sequence (50 ng) GAAGCACTGGGGGAGACGCA (SEQ ID NO:7) with 183 nt donor oligo (40 ng) (GCCCTCAACACCACGGTGCTGCAGGGGCATGGCCGGCCAGTCCTTGAGGGGTGTCA TGTACTTATGACGCCTTGAAGCACTGGGGGAGACACAaGCaTGGTGTCGGCAGC TGGGTGAGGAGGGCCCATGCCAGCGTGTGGTGAGCACACACGGTGTGTGGCTGC TGGCCTTCCTGAAGAAGCGG, SEQ ID NO:8) containing a nucleotide G>A point mutation (underlined uppercase "A" at nt 89 in SEQ ID NO:8) for amino acid sequence change at R47H and 2 silent mutations (lysine AAG>AAA (underlined lower case "a" at nt 93 in SEQ ID NO:8) and alanine GCC>GCA (underlined lower case "a" at nt 96 in SEQ ID NO:8)) into the gene (to prevent re-cutting of the donor sequence in homologous directed repair). The CRISPR strategy resulted in the specific R47H knock in, and silent mutations present in the Trem2 gene of founder mice.

[00161] Offspring carrying the modified allele in the germ-line were interbred to generate the homozygous genetically modified genome. All F1 matings produced normal litter sizes with a Mendelian distribution of the locus. The resulting inbred strain of mouse is designated C57BL/6J-Trem2^{em1Adpnc}/J (common name Trem2 R47H KI (JAX)) and expresses Trem2p.

[00162] Generation of A Genetically Modified Mouse Having a DNA Sequence Encoding APOE4p and a DNA Sequence Encoding Trem2p in Its Genome

- 40 -

[00163] In this example, a genetically modified mouse was generated by crossing an inbred strain of mouse, B6(SJL)-*Apoe*^{tm1.1(APOE*4)Adpmc}/J (common name APOE*4 KI (JAX)) expressing human APOE4p with an inbred strain of mouse, C57BL/6J-*Trem2*^{em1Adpmc}/J (common name Trem2 R47H KI (JAX)) expressing mouse Trem2p. The resulting genetically modified mice, homozygous for both the humanized *APOE4* allele and the R47H allele of the mouse *Trem2* gene, are designated B6(SJL)-*Apoe*^{tm1.1(APOE*4)Adm} *Trem2*^{em1Adm}/J (formerly B6(SJL)-*Apoe*^{tm1.1(APOE*4)Adpmc} *Trem2*^{em1Adpmc}/J, abbreviated as APOE4 X Trem2 R47H (JAX) mice), common name: B6J.APOE4/Trem2, which express both human APOE4 and mouse Trem2p.

10 [00164] Validation of Genetically Modified Mouse Model of Non-Familial Late-Onset Alzheimer's Disease

[00165] Tissue Harvesting, Protein Isolation and Sectioning

[00166] Mice were administered a lethal dose of Ketamine/Xylazine by intraperitoneal injection, and transcardially perfused with 1xPBS (phosphate buffered saline). Brains were dissected, and the right hemisphere was snap frozen for protein isolation, while the left hemisphere was fixed in 4% paraformaldehyde overnight at 4°C. The fixed hemispheres were rinsed with 1xPBS, cryoprotected in 10% sucrose, followed by 30% sucrose at 4°C, and finally embedded in OCT (optimal cutting temperature compound). Frozen brains were sectioned at 25 µm and stored at -80°C until required. Protein was extracted with Trizol Reagent (Life Technologies, Cat#15596-018) following manufacturer's guidelines. Protein pellets were resuspended in a solution of 1:1 8M urea and 1% SDS.

[00167] Immunofluorescence, Thioflavin S Staining, and Image Capture

[00168] Cryosections were rinsed with PBT (1xPBS with 1% TritonX-100) for 5 minutes (mins) then incubated with 500 µL of Liberate Antibody Binding Solution (L.A.B. - Polysciences Inc.) solution for 20 minutes at room temperature (RT) for antigen retrieval. Slides were then incubated overnight at 4°C in the following primary antibodies: rabbit polyclonal anti-GFAP (1:200, Dako); rabbit polyclonal anti-IBA1 (1:250, Wako); rabbit polyclonal anti-NeuN (1:100, Cell Signaling Inc); mouse monoclonal anti-non-phosphorylated neurofilament (1:200, Covance) and sheep polyclonal anti-TREM2 (1:200, RD Systems). The sheep polyclonal anti-TREM2 antibody was previously verified using Trem2 deficient mice. All antibodies were diluted in PBTB (1xPBS, 1% TritonX-100 and 1% BSA) containing 10% normal goat or donkey serum. After primary incubation, sections were

- 41 -

washed 3 times in PBT and incubated with appropriate secondary antibodies (goat anti-rabbit Alexa Fluor 488/594/633, goat anti-mouse Alexa Fluor 488, donkey anti-sheep Alexa Fluor 594, 1:1000 dilution, Life Technologies) for 2 hrs at RT.

[00169] All sections were then counterstained with DAPI and mounted with Aqua PolyMount (Polysciences). For Thioflavin S staining, sections stained with IBA1 and GFAP were further counterstained with 1% Thioflavin S (diluted in a 1:1 water:ethanol ratio). Slides were incubated for 8 mins at RT in 1% Thioflavin-S, washed in 80% ethanol, then 95% ethanol and finally in dH₂O and mounted. Images were taken using either the Leica SP5 confocal microscope or the Zeiss Axio Imager.Z2. For each antibody, all images were captured using identical parameters for accurate quantification.

[00170] Initial observations were performed in sections from both males and females. Quantification of cell numbers was performed on brain sections from at least 4–6 male mice, as there was no overt difference between sexes. For plaque counts, the number of plaques present in the entorhinal cortical region for each mouse was determined. For IBA1+ cells, 5 equally spaced images were captured (using 20× optical lens) of either the cortex, in the region of the entorhinal cortex, or the hippocampus, from a central brain section of each mouse. For NeuN+ cells, 5 equally spaced images were captured (using 20× optical lens). For IBA1+ cells associated with plaques, images of 8+ plaques per brain were imaged (using 20× optical lens).

[00171] Images were processed and all cells in the 20× image were counted using the cell counter plugin for ImageJ/FIJI. A single cell was determined as a DAPI stained nucleus associated with a cell specific antibody stain (e.g. IBA1 or NEUN). Cell numbers in the 5 images from each mouse were totaled and then averaged across mice. Mouse number and diet were masked to the investigator for all cell counting assays.

[00172] Western blot analysis demonstrates expression of human APOE4 in B6(SJL)-*ApoE*^{tm1.1(APOE*4)Adng} *Trem2*^{em1Adng}/J (common name: B6J.APOE4/Trem2) mice

[00173] Brain extracts (~25 micrograms protein) were diluted in 2x Laemmli sample buffer (Bio-Rad 1610737) and run on a 4-20% gradient (BioRad mini-protean TGX 456-1096) and transferred to a nitrocellulose membrane (InVitrogen IB301001).

[00174] Blots were blocked with 5% non-fat milk powder and probed overnight at +4°C with a human APOE4-specific antibody (Novus Biologicals NBP1-49529) at 1:100 dilution. Blots were then probed with secondary antibody (Millipore goat anti-mouse HRP AP191P) at 1:30,000 dilution for 2 hours at room temperature. Blots were detected using ECL.

chemiluminescent reagents (GE Healthcare RPN 2109) on Amersham Hyperfilm ECL (GE Healthcare 28906838).

[00175] An antibody that is specific for the human APOE4 variant (Novus Biologicals NBP1-49529 at 1:100 dilution) was used to probe Western blots of about 25 micrograms of protein from C57BL/6J (abbreviated B6J) or B6J.APOE4/Trem2 brain tissue. Figure 2 is an image of a Western blot of brain tissue from B6J.APOE4/Trem2 (lanes 4-6) and control (WT (B6J); lanes 1-3) brain tissue. As shown in Figure 2, human APOE4 protein expression was detected only in the protein from B6J.APOE4/Trem2 mice.

[00176] Blood chemistry shows altered metabolism in the B6J.APOE4/Trem2 mice

[00177] APOE variants have been shown to differentially regulate lipoprotein and cholesterol metabolism. Although the mechanisms by which the APOE4 variant increases the risk for Alzheimer's disease is not known, these effects on altered metabolism are thought to play a role. Blood samples obtained from 12 month old B6J.APOE4/Trem2 (abbreviated APOE4/Trem2 in Figures 3A, 3B and 3C) mice and 12 month old C57BL/6J control mice were assayed for high density lipoprotein (HDL), low density lipoprotein (LDL) and total cholesterol according to standard blood chemistry methods.

[00178] Blood, extracted at harvest, was stored in EDTA coated vials on ice and further centrifuged at 5000 RPM for 15mins. The plasma was removed and aliquoted for long term storage at -80°C. Plasma aliquots were profiled for the following: Total cholesterol (mg/dL), LDL (mg/dL), HDL (mg/dL)). High density lipoprotein cholesterol (HDL) was assayed using the Wako L-Type HDL-C kit (Wako 99100101) as per manufacturer's instructions. LDL was assayed using Beckman Coulter LDL-Cholesterol kit (Beckman Coulter OSR6196) as per manufacturer's instructions. Total cholesterol was assayed using the Beckman Coulter Cholesterol kit (Beckman Coulter OSR6116).

[00179] Results are shown in Figures 3A, 3B, and 3C, respectively. These data show that the B6J.APOE4/Trem2 mouse has APOE4-dependent alterations in cholesterol metabolism, including reduced total cholesterol and reduced levels of both LDL and HDL.

[00180] Immunohistochemistry shows cerebrovascular leakage and inflammation in the B6J.APOE4/Trem2 mice

[00181] All mice were bred and housed in a 12/12 hours light/dark cycle. Eight month old mice were injected intraperitoneally with a lethal quantity of ketamine/xylazine according to IACUC approved procedures. Mice were perfused with 1X PBS (phosphate buffered saline) and whole brains were removed. One hemisphere was fixed in 4% paraformaldehyde

- 43 -

overnight at +4°C. Following fixation, the tissue was rinsed in 1X PBS, incubated in 10% sucrose overnight at +4°C, then incubated in 30% sucrose overnight at 4°C. Brains were then frozen in optimal cutting temperature (OCT) compound and stored at -80°C until sectioned. Frozen brains were sectioned at 25 microns and mounted on glass slides, and stored at -80°C until required for immunofluorescence staining.

[00182] Slides were dried and post fixed in 4% PFA. Sections were subsequently immersed in diH₂O for 3mins at 37°C, then transferred and incubated in 0.5mg/mL pepsin in 0.2N HCl for 15mins at 37°C. Sections were further washed in diH₂O for 3mins, transferred to a humidified chamber, and washed in 1xPBS. Sections were incubated overnight in Rabbit anti-fibrin (1:200) and Goat anti-ColIV (anti-collagen IV) (1:40) at +4°C in 1xPBT. Slides were washed in 1xPBT and incubated in the appropriate secondary antibodies at a concentration of 1:1000 (Donkey anti-rabbit IgG 594, Donkey anti-goat 488) for 2 hours at room temperature. Tissue was counterstained with DAPI and mounted using Aqua-Poly mount (Polyscience Inc). Staining was imaged on the Zeiss AxioImager at a magnification of 20x.

[00183] Sagittal brain sections of B6J.APOE4/Trem2 mice were immunostained for fibrinogen (fibrin) to detect cerebrovascular leakage. Representative images of B6J.APOE4/Trem2 tissue at 7-8 months of age are shown in Figure 4 along with representative images from similar sagittal sections of brain from control C57BL/6J (abbreviated B6J) mice. Arrows indicate cerebrovascular leakage as indicated by fibrin immunostaining outside of blood vessels. Blood vessels are shown by immunostaining for collagen IV (Col IV).

[00184] Vascular damage may be a key aspect of late-onset Alzheimer's disease pathology. Some existing mouse models of familial Alzheimer's disease have demonstrated cerebral amyloid angiopathy (CAA), but B6J.APOE4/Trem2 mice are the first model that does not over-express familial Alzheimer's disease mutations to show vascular deficits.

[00185] Transcriptional analysis demonstrates AD-relevant changes in gene expression in the B6J.APOE4/Trem2 model

[00186] Gene expression analysis was carried out with the NanoString Neuropathology gene panel. This assay measures the expression of 770 neuropathology-related genes. Female mice around eight months of age were assayed for the B6J.APOE4/Trem2 strain and the C57BL/6J (abbreviated B6J) strain, with three biological replicates of each strain.

- 44 -

[00187] Total RNA was extracted from brain homogenates. Tissues were lysed and homogenized in TRIzol Reagent (Ambion), then RNA was isolated using the miRNeasy Mini kit (Qiagen), according to manufacturers' protocols, including the optional DNase digest step. Sample concentration and quality were assessed using the Nanodrop 2000 spectrophotometer (Thermo Scientific) and the RNA 6000 Nano LabChip assay (Agilent Technologies).

[00188] RNA was hybridized and multiplexed with NanoString probes according to manufacturer's instructions. Counts for target genes were normalized to housekeeping genes to account for variability in RNA content. Data were analyzed using Nanostring nSolver Analysis Software.

[00189] Expression of each gene in the B6J.APOE4/Trem2 strain was compared to the control C57BL/6J strain and genes with significant ($p < 0.05$) expression were identified with a linear regression model as shown in Figure 5. Figure 5 is a gene expression heatmap of differentially-expressed genes in B6J.APOE4/Trem2 compared to C57BL/6J. Expression values are in Log2 fold change relative to the C57BL/6J average of each gene.

[00190] The probe used in this panel detects mouse Apoe but not human APOE. Because in this model mouse Apoe has been replaced by the human APOE4 variant, no Apoe expression is detected and this is shown as the most strongly down-regulated transcript.

[00191] The list of differentially-expressed genes contains multiple genes related to brain function and neurodegeneration. The Gene Ontology Biological Process and Panther Pathway annotations database was queried to identify processes and pathways represented by these genes. The relevant processes include, but are not limited to, the results in Table I which shows pathways and processes represented by the differentially-expressed genes in the B6J.APOE4/Trem2 strain. Notably, these interlinked processes and pathways include many highly relevant to neurodegeneration.

TABLE I	
Process or Pathway	Genes
Alzheimer's disease-amyloid secretase pathway	Pcsk2, Mapk10, Mapk9, Prkcq
5HT2 type receptor mediated signaling pathway	Slc18a2, Plcb2, Slc6a4, Gng2, Prkcq
Inflammation mediated by chemokine and cytokine signaling pathway	Akt3, Gnao1, Plcb3, Arrb2, Il6, Myh10, Gng2
Modulation of chemical synaptic transmission	Cnr1, Stx1a, Arrb2, Unc13a, Cdk5, Calb1, Slc6a4, Gria4

- 45 -

Neuron development	Cnr1, Thy1, Mapk10, Hcn1, Cdk5, Chl1, Il6, Mapk9, Myh10, Uchl1
Cognition	Cnr1, Amph, Cdk5, Calb1, Chl1, Slc6a4, Chmp2b
Apoptosis signaling	Akt3, Mapk10, Mapk9, Casp7, Prkcq
Aging	Cnr1, Slc18a2, Gnao1

[00192] Scientific and technical terms used herein are intended to have the meanings commonly understood by those of ordinary skill in the art. Such terms are found defined and used in context in various standard references illustratively including J. Sambrook and D.W.

- 5 Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press; 3rd Ed., 2001; F.M. Ausubel, Ed., Short Protocols in Molecular Biology, Current Protocols; 5th Ed., 2002; B. Alberts et al., Molecular Biology of the Cell, 4th Ed., Garland, 2002; D.L. Nelson and M.M. Cox, Lehninger Principles of Biochemistry, 4th Ed., W.H. Freeman & Company, 2004; Herdewijn, P. (Ed.), Oligonucleotide Synthesis: Methods and Applications,
- 10 Methods in Molecular Biology, Humana Press, 2004; A. Nagy, M. Gertsenstein, K. Vintersten, R. Behringer (Eds) 2002, Manipulating the Mouse Embryo: A Laboratory Manual, 3rd edition, Cold Spring Harbor Laboratory Press, ISBN-10: 0879695919; and K. Turksen (Ed.), Embryonic stem cells: methods and protocols in Methods in Molecular Biology, 2002; 185, Humana Press; Current Protocols in Stem Cell Biology, ISBN:
- 15 9780470151808.

- 46 -

SEQUENCES

[00193] The amino acid sequence of APOE4p is shown along with exemplary nucleic acid sequences encoding APOE4p.

[00194] SEQ ID NO:1: APOE4p (317 amino acids)

5 MKVLWAALLVTFLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDY
LRWVQTLSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRAR
LSKELQAAQARLGADMEDVRGRLVQYRGEVQAMLGQSTEELRVRLASHLRKLRKR
LLRDADDLQKRLAVYQAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPL
QERAQAWGERLRARMEEMGSRTDRDLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQ
10 ARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH

[00195] SEQ ID NO:2: Exons 2, 3 and 4 of the human APOE4 genomic DNA sequence encoding human APOE4p including the 18 amino acid signal peptide

15 ACTGGCCAATCACAGGCAGGAAGATGAAGGTTCTGTGGGCTGCGTTGCTGGTCA
CATTCCTGGCAGGTATGGGGGCGGGGCTTGCTCGGTTCCCCCGCTCCTCCCCCT
CTCATCCTCACCTCAACCTCCTGGCCCCATTACAGGCAGACCCTGGGCCCCCTCTTC
TGAGGCTTCTGTGCTGCTTCCTGGCTCTGAACAGCGATTTGACGCTCTCTGGGCCT
CGGTTTCCCCCATCCTTGAGATAGGAGTTAGAAGTTGTTTTGTTGTTGTTGTTTGT
TGTTGTTGTTTTGTTTTTTTGAGATGAAGTCTCGCTCTGTGCGCCAGGCTGGAGTG
20 CAGTGGCGGGATCTCGGCTCACTGCAAGCTCCGCCTCCCAGGTCCACGCCATTCT
CCTGCCTCAGCCTCCCAAGTAGCTGGGACTACAGGCACATGCCACCACACCCGA
CTAACTTTTTTGTATTTTCAGTAGAGACGGGGTTTCACCATGTTGGCCAGGCTGGT
CTGGAACCTCCTGACCTCAGGTGATCTGCCCCGTTTCGATCTCCCAAAGTGCTGGGA
TTACAGGCGTGAGCCACCGCACCTGGCTGGGAGTTAGAGGTTTCTAATGCATTGC
25 AGGCAGATAGTGAATACCAGACACGGGGCAGCTGTGATCTTTATTCTCCATCACC
CCCACACAGCCCTGCCTGGGGGCACACAAGGACACTCAATACATGCTTTTCCGCTG
GGCGCGGTGGCTCACCCCTGTAATCCCAGCACTTTGGGAGGCCAAGGTGGGAGG
ATCACTTGAGCCCAGGAGTTCAACACCAGCCTGGGCAACATAGTGAGACCCTGT
CTCTACTAAAAATACAAAAATTAGCCAGGCATGGTGCCACACACCTGTGCTCTCA
30 GCTACTCAGGAGGCTGAGGCAGGAGGATCGCTTGAGCCCAGAAGGTCAAGGTTG
CAGTGAACCATGTTACAGGCCGCTGCACTCCAGCCTGGGTGACAGAGCAAGACCC
TGTTTATAAATACATAATGCTTTCCAAGTGATTAAACCGACTCCCCCCTCACCCCTG
CCCACCATGGCTCCAAAGAAGCATTGTGTGGAGCACCTTCTGTGTGCCCCCTAGGTA
CTAGATGCCTGGACGGGGTCAGAAGGACCCTGACCCACCTTGAACCTGTTCCACA
35 CAGGATGCCAGGCCAAGGTGGAGCAAGCGGTGGAGACAGAGCCGGAGCCCGAG
CTGCGCCAGCAGACCGAGTGGCAGAGCGGCCAGCGCTGGGAACCTGGCACTGGGT
CGCTTTTGGGATTACCTGCGCTGGGTGCAGACACTGTCTGAGCAGGTGCAGGAGG
AGCTGCTCAGCTCCCAGGTCACCCAGGAACCTGAGGTGAGTGTCCCCATCCTGGCC
CTTGACCCTCCTGGTGGGCGGCTATACCTCCCCAGGTCCAGGTTTCATTCTGCCCC
40 TGTCGCTAAGTCTTGGGGGGCCTGGGTCTCTGCTGGTTCTAGCTTCCTCTTCCCAT
TTCTGACTCCTGGCTTTAGCTCTCTGGATACTCTCTCTCAGCTTTGTCTCTCTCTC
TTCCCTTCTGACTCAGTCTCTCACACTCGTCCTGGCTCTGTCTCTGTCTTCCCTAG
CTCTTTTATATAGAGACAGAGAGATGGGGTCTCACTGTGTTGCCAGGCTGGTCT
TGAACCTCTGGGCTCAAGCGATCCTCCCGCCTCGGCCTCCCAAAGTGCTGGGATT
45 AGAGGCATGAGCCACCTTGCCCCGGCCTCCTAGCTCCTTCTTCGTCTCTGCCTCTGC
CCTCTGCATCTGCTCTCTGCATCTGTCTCTGTCTCCTTCTCTCGGCCTCTGCCCCGT

- 47 -

TCCTTCTCTCCCTCTTGGGTCTCTCTGGGCTCATCCCCATCTCGCCCCGCCCATCCC
 AGCCCTTCTCCCCGCCTCCCACTGTGCGACACCCTCCCGCCCTCTCGGGCCGCAGG
 GCGCTGATGGACGAGACCATGAAGGAGTTGAAGGCCTACAAATCGGAACTGGAG
 GAACAACTGACCCCCGGTGGCGGAGGAGACGCGGGGCACGGCTGTCCAAGGAGCT
 5 GCAGGCGGGCGCAGGCCCCGGCTGGGGCGCGGACATGGAGGACGTGCGCGGGCCGCC
 TGGTGCAGTACCGCGGGCGAGGTGCAGGCCATGCTCGGCCAGAGCACCGAGGAGC
 TCGGGGTGCGCCTCGCCTCCACCTGCGCAAGCTGCGTAAGCGGCTCCTCCGCGA
 TGCCGATGACCTGCAGAAGCGCCTGGCAGTGTACCAGGCCGGGGCCCCGCGAGGG
 CGCCGAGCGCGGGCCTCAGCGCCATCCGCGAGCGCCTGGGGGCCCTGGTGGAAACA
 10 GGGCCGCGTGCGGGGCCCACTGTGGGCTCCCTGGCCGGCCAGCCGCTACAGGA
 GCGGGCCCAGGCCTGGGGCGAGCGGCTGCGCGCGCGGATGGAGGAGATGGGCA
 GCCGGACCCGCGACCGCCTGGACGAGGTGAAGGAGCAGGTGGCGGAGGTGCGC
 GCCAAGCTGGAGGAGCAGGCCCAGCAGATACGCCTGCAGGCCGAGGCCTTCCAG
 GCCCCGCTCAAGAGCTGGTTCGAGCCCCCTGGTGGAAAGACATGCAGCGCCAGTGG
 15 GCCGGGCTGGTGGAGAAGGTGCAGGCTGCCGTGGGGCACCAGCGCCGCCCTGTG
 CCCAGCGACAATCACTGAACGCCGAAGCCTGCAGCCATGCGACCCCCACGCCACC
 CCGTGCCTCCTGCCTCCGCGCAGCCTGCAGCGGGAGACCCTGTCCCCGCCCCAGC
 CGTCCTCCTGGGGGTGGACCCTAGTTTAATAAAGATTACCAAGTTTCACGCA

20 [00196] SEQ ID NO:3: Trem2p (249 amino acids, R47H mutation)

MGPLHQFLLLLITALSQALNTTVLQGMAGQSLRVSCITYDALKHWGRHKAWCRQLG
 EEGPCQRVVSTHGVWLLAFLKKRNGSTVIADDTLAGTVTITLKNLQAGDAGLYQCQ
 SLRGREAQVLQKVLVEVLEDPLDDQDAGDLWVPEESSFEGAQVEHSTSRQVSSCGS
 PLAYHLPPLSKESRDLLPTHLHSSPPGLRSPEQVSCSQHPLGCGQGQAEAGNTCGQR
 25 AGLWPRCWAPTSDPHWTRRYVREF

[00197] SEQ ID NO:4: mutated mouse genomic DNA sequence encoding Trem2p (1056 nucleotides)

ACTTCAAGGGAAAAGCAAGATCTTGCACAAGGTCCCCTCCGGCTGGCTGCTGGC
 30 AAAGGAAAGGTGCCATGGGACCTCTCCACCAGTTTCTCCTGCTGCTGATCACAGC
 CCTGTCCCAAGCCCTCAACACCACGGTGCTGCAGGGCATGGCCGGCCAGTCCTTG
 AGGGTGTCATGTACTTATGACGCCTTGAAGCACTGGGGGAGACACAAaGCaTGGT
 GTCGGCAGCTGGGTGAGGAGGGGCCCATGCCAGCGTGTGGTGAGCACACACGGTG
 TGTGGCTGCTGGCCTTCCTGAAGAAGCGGAATGGGAGCACAGTCATCGCAGATG
 35 ACACCCTTGCTGGAACCGTCACCATCACTCTGAAGAACCTCCAAGCCGGTGACGC
 GGGCCTCTACCAGTGTGAGAGTCTCCGAGGCCGAGAGGCTGAGGTCTTGCAGAA
 AGTACTGGTGGAGGTGCTGGAGGACCCTCTAGATGACCAAGATGCTGGAGATCT
 CTGGGTCCCCGAGGAGTCATCGAGTTTCGAGGGTGCCCAAGTGGAACACAGCAC
 CTCCAGGCAGGTTTCATCCTGTGGGTACCTCTAGCCTACCACCTTCCTCCTCTTT
 40 CCAAGGAATCAAGAGACCTCCTTCCCACCCACCTCCATTCTTCTCCTCCTGGCCT
 GCGTTCTCCTGAGCAAGTTTCTTGCAGCCAGCATCCTCTGGGCTGTGGCCAGGGG
 CAGGCAGAAGCCGGGAACACCTGTGGTCAGAGGGCTGGACTGTGGCCAAGATGC
 TGGGCACCAACTTCAGATCCTCACTGGACCCGGAGGTACGTGAGAGAATTCTGA
 GTGGGAGGAGAACTACAGCTTAAGTCCAGCCAGGAGTCAATCCAGCCTGCATGC
 45 TCTCCCCCTCCTCCACCAAGACTTCTGTTTCTGCTACTTTTGCTTCAGAGGCCGCC
 CTGCCTCAAGCCCACCTATCCTGGGAGCAGGAATACTGGTGTGTACATCTGTGTT
 GAGTGGGGAAGACAGCTGGATGGTTGTCTGTCAACTTCTGCACTTTGGACATTAA

- 48 -

ACATTCTCCACACACCAA

[00198] SEQ ID NO:5: Trem2p (249 amino acids, mouse wild type protein, no R47H mutation)

5 MGPLHQFLLLLITALSQALNTTVLQGMAGQSLRVSCITYDALKHWGRRKAWCRQLG
EEGPCQRVVSTHGVWLLAFLKKRNGSTVIADDTLAGTVTITLKNLQAGDAGLYQCQ
SLRGREAENVLQKVLVEVLEDPLDDQDAGDLWVPEESSSEFEGAQVEHSTSRQVSSCGS
PLAYHLPLSKESRDLLPTHLHSSPPGLRSPEQVSCSQHPLGCGQGQAEAGNTCCQR
AGLWPRCWAPTSDPHWTRRYVREF

10

[00199] SEQ ID NO:6: mouse wild type genomic DNA sequence encoding Trem2 mouse wild type protein (1056 nucleotides)

ACTTCAAGGGAAAAGCAAGATCTTGCACAAGGTCCCCTCCGGCTGGCTGCTGGC
AAAGGAAAGGTGCCATGGGACCTCTCCACCAGTTTCTCCTGCTGCTGATCACAGC
15 CCTGTCCCAAGCCCTCAACACCACGGTGCTGCAGGGGCATGGCCGGCCAGTCCTTG
AGGGTGTCATGTACTTATGACGCCTTGAAGCACTGGGGGAGACGCAAGGCCTGG
TGTCGGCAGCTGGGTGAGGAGGGCCCATGCCAGCGTGTGGTGAGCACACACGGT
GTGTGGCTGCTGGCCTTCCTGAAGAAGCGGAATGGGAGCACAGTCATCGCAGAT
GACACCCTTGCTGGAACCGTCACCATCACTCTGAAGAACCTCCAAGCCGGTGAC
20 GCGGGCCTCTACCAGTGTGAGAGTCTCCGAGGCCGAGAGGCTGAGGTCCTGCAG
AAAGTACTGGTGGAGGTGCTGGAGGACCCTCTAGATGACCAAGATGCTGGAGAT
CTCTGGGTCCCCGAGGAGTCATCGAGTTTCGAGGGTGCCCAAGTGGAACACAGC
ACCTCCAGGCAGGTTTCATCCTGTGGGTACCTCTAGCCTACCACCTTCCTCCTCT
TTCCAAGGAATCAAGAGACCTCCTTCCCACCCACCTCCATTCTTCTCCTCCTGGCC
25 TCGGTTCTCCTGAGCAAGTTTCTTGCAGCCAGCATCCTCTGGGCTGTGGCCAGGG
GCAGGCAGAAGCCGGGAACACCTGTGGTCAGAGGGCTGGACTGTGGCCAAGATG
CTGGGCACCAACTTCAGATCCTCACTGGACCCGGAGGTACGTGAGAGAATTCTG
AGTGGGAGGAGAACTACAGCTTAAGTCCAGCCAGGAGTCAATCCAGCCTGCATG
CTCTCCCCTCCTCCACCAAGACTTCTGTTTCTGCTACTTTTGCTTCAGAGGCCGCC
30 TCTGCCTCAAGCCACCTATCCTGGGAGCAGGAATACTGGTGTGTACATCTGTGT
TGAGTGGGGAAGACAGCTGGATGGTTGTCTGTCAACTTCTGCACCTTGGACATTA
AACATTCTCCACACACCAA

[00200] SEQ ID NO:7: Trem2 CRISPR guide

35 GAAGCACTGGGGGAGACGCA

[00201] SEQ ID NO:8: Trem2 repair oligo (183 nucleotides) containing a nucleotide G>A point mutation (at nucleotide 89 in this oligo sequence) for amino acid sequence change at R47H and 2 silent mutations (lysine AAG>AAA (at nucleotide 93 in this oligo sequence) and alanine GCC>GCA (at nucleotide 96 in this oligo sequence)) into the gene to prevent re-

cutting of the donor sequence in homologous directed repair:

GCCCTCAACACCACGGTGCTGCAGGGGCATGGCCGGCCAGTCCTTGAGGGTGTCA
TGTA

- 49 -

TGGGTGAGGAGGGCCCATGCCAGCGTGTGGTGAGCACACACGGTGTGTGGCTGC
TGGCCTTCCTGAAGAAGCGG

[00202] SEQ ID NO:9: 5' homology arm (4980 nucleotides: mouse Apoe4 exon 1 and
5 757 nucleotides of mouse Apoe4 intron 2 sequence) included in the "humanized" mouse
ApoE construct inserted into the mouse genome.

CCTGTATCTCAGGGTTGAGAGGGAAGAGAGTGGGGTTTCCAGATGCCCACATCC
CTTGATACCTAGTCCTCACCCAACCTCTGCTCTCCTAGTGAACAACCTGGTTGGCTAC
AGTAACGCTGGGGCCAGGCAGGCATGCATGCGACGTATTACCACAAAGCCAGTGA
10 CCAGGTGAGCCGGAGGGAGCGCCTAGCTGTGGGTCCCAGGCTGGGTTTGCTGGT
GCAGTTGGTATGCCCAGGAGTCCTAATGGGGCCACTCACATGTGTGCCGGGGCCCTC
TCTCCCCCAGCTGCAGGTGGGTGTGGAGTTTGAGGGCCAGCACCAAGGATGCAGGA
CACCAGTGCCTCCTTTGGGTATCAGCTGGACCTGCCCAAGGCCAACTTCCTTTTTTA
AAGGTAAGGAAGGCCTCAGCTTCCCTCCTGGGGGAACAGGCCAGATAAGACTCAG
15 CTGTCTGTGGTAGAGTCCATGGGAAATAGGGAGGTTGAACATGTGCTGGTGGAG
TGGGCGGGGACTCTGTGCAGCTCCAAATTACTCTGGGTGGCTTGTCAAACAGTGG
GGCTCCTACCCTGGCATGTTTAGTACATGTTGGGGGGCCTCGCTTTAAGCCCTCTCT
TCCCATTTCCCATCTAGCAAGCTCTCTGGCCCTCCCCACTCACTCTTACCTTACTTG
GAGTTCTTCTATTGTGTGATGAAACACTATGATGGTAAACAGCTTAGGGAGCAAA
20 GAGGTTATGTTGGGTTACAACCTCTCAGGTGGCATGCCTACCCTGAGGAGAAGAT
GGGGCAGGACTCAGCAGAAAGCTGAAGGCAAGCTGATGCAGAAGGCCTTGTGG
GAGTGCTGCTTGTGGCTTGTCTCCTTATGGCTTCCTCAGCCTGCTCTTATAGCCTC
CGGACCATTAGCCCAGGGTGCCCCACTGAAAATAATCTGGGTACTCCCACATCA
ATCACTTAGAAAGTGCCCTACAGGCTTGCCTGCTGCCCTAGCTAATGGAGACATA
25 TGTATTGAGGTTCCCTCAGCTGGATCTCTTGAGTTCAAGACCAGCCTGGTCTACA
GAGCAAGTTCTGGGACAGCCAGGGCTACCCAGAGAAACCCTGTCTCAGAAAAGA
AAAAAAAGAAAAAGGTGGGGGTGGGGTGACTAGCTTGTATAAAACTAGCCAGC
ACAGCAGGGAAGCTGTGTGAATAGTGACAGCCAGGTTTCAGAACCTCATTCTGCG
CAGTGACATGGGTTTGTCAAGCCTGGGCGGTGTTGAGCCACTTAAAGGGTTGCTG
30 TGATGGTCTGGAGTGGCCTTGGTTGTGACTTAGGACATACGGGTCCGTTGTGGCT
ACCATAGAGATGGGTGGCCAGGCACATCAAGCCACCCAGTCTCTGCCCCGCTCTC
GGCCCACAGGCTCTGTGAACAGTAACTGGATCGTGGGCGCCACGCTGGAGAAGA
AGCTTCCGCCCTTGCCCCCTGACACTGTCCCTCTGCGCCTTCCTGAACCACCGCAA
GAATAAGTTCCTGTGTGGCTTCGGCCTCACCATCGGCTGAGCCCTCCTGTCTTCC
35 TCTGCAGACCATCGCTGGGCGCGGCTGCCCTCCCCCTCCTCTCCCTCTCTCTTGGGGT
TGGGGCAGTGGGAAGGAGGGGACCTCCCATGCCCAAGGATCCCCAGCGCCAGGG
GACAGTGCCCAGGGGGCCTGGGGTCCCGGAGGGAGTCTGGGATCTGAAGGGCA
TTCGATTGTGAGCGCCCAGGCAGAGGGCGCAGAGGCGGCTGTACACAGGCTCAGA
AAGGAAAGACTTGATGTCCTCCTGAGGGCAGCAGAGGAGCGCCGAGCCGCCTGT
40 CACTTCCCCCTCCACCCCTCCATAGAAATCATGTTTATAAGTTATGGAAAACCGG
GACATTTTACAGAAAAAATAAACTTAAAAAACAATAATACGTGGAAAAA
AAAATAGGATCTGGGAGGCCTCGGTTTTCTCCAGTTGTTGACATGGTTGCCAGCA
GGCGGCGCCGAGGGTTCAGAAAGCACAGCAGCACCAAGCAGTTTAGAGAAAGCT
TGGCCAGGCATGGTCAACCCCTCTGCTCTTGGGGACTTACACTGCCGGAACATCA
45 GAGGCCTGGCCTCACCAGGAGGGTGGCTCCAGGTCACCTCGCCTCTGTGCAGTCTG
GCCCCGAGAGCTGGCAGAGGACTTTGTCTCTGTAAACAGGGTGGGGGCAGGGAG
ACGGGGCTCAGGAGCCTCCCTGTCCCAAAACGGGCTGAGGTGGTAGCTTGTGCT

- 50 -

GACTTTCTCCCAGTGGGAAGGTCAGAGGTCTCAGAACTTCAGGAAGAAACGGA
 GTTCCTGGAAGTTCAGCACATAAGGAAAGTTACTCTGGGAGGAACGGGCCCTA
 GCACCTTCCCAGGCTGAAACAGGAAATGTCAAGTTGTTTTGTTTTTTAAATTTTGT
 TGAAGATGTAGCTCTGGGCCTCACGTGTCAGGCAGGTGCTGCTGGGTTCCTATA
 5 GTGCTTTTCCGTGAGGCCTGCTCTGGGGTGTGCGATAAGGGCCTCAGATTGGGCT
 CTGCATCTCACTGCTGCACCTCATGGCATCCCAAGGGAAGCAAAGACTCACGAT
 GAACTGGTCAGTGTCTAGACCGCAGCACTAAGACCCTCTCTACTGCCTGGGCTG
 GAGATGGGAGCTGGCCCTTAGCAACCCATGAAAATCATCTCACCACACCCAGTC
 CTTGCCAGTGTCTTCTGAAGCCAAAGCTAACAGGCCTGGGCCTGGCCAGGCACCC
 10 TGTACGTACCCTTGGAGCCAGGTGTTCCGCCTCTGCCCATCCTGCAGAATCATGT
 TTTGCCGTGTCTGGTGCCAAACACTGCTATGTGGCTTCTCTCCTGCCATCAACAGC
 TGGGAACAGGGAACCTTGTGCAGGCAGTGCTTCTAGCAAGCTTGCTGTGGTCTCT
 GAGCCCCCTTGCTCCTACCTGACTTCCCAGGTACAATGGCTTTCCCACTTTTTGGGGG
 TTTTGTGTGTGTGGGTTTTTTTTTTTGTTTTTTCAAGACAGGGTTTCTCTGTGTAGTCC
 15 TGTCCGTCCTGGAACCTCACTTTGTAGACCAGGCTGGCCTCCAACCTCAGAAATTCA
 CCTGCCTCTGCCTCCAAGTGCTGGGATTATGGGATTAAAGGCATGTGCCACCACG
 CCCAGCTGGCTTTTCCACTTTTGTAGCCAGGACTTCATTCTATTACCTGAGCTCGGG
 ATCTTCCTGCCTCAGCTTTGCATATGGCTAGCACTATAGACCCATGTTCCAGTGA
 ATGACTTATGGCTTGTCTTTTTTTTTTTTTTTTTTTTTTTTATGTGCATTAGTGTTT
 20 TGCCTGCATGTATGCCTTCGTGAGGGTAGCAGATCTTGGTGTTACAGTTGTGAGC
 TGCTGTGTGGGTGCTGCGATTTTGAACCTAGGTCCTGTGAAATGCAGTCAGTGCT
 CCTAACCTCTGAGTCATCTCTCCAGCTCCTGCTCTTCTGCTTTTATGAGGAAAAAG
 AAAAGAGAAGTGGCTTGAGAGTGGAAAATGCACATGCAGGGGTGCACACCTGCA
 GTCCCAGCATGCTACAGCAGAGGCAGAAGGACCTTTGTGGGTAGAGGGGCAGCC
 25 TGAGAATCTTATCTCAAAACAACCTTTTTTAAAATGTGCTCTGTAGGGGTAGCTCTT
 CCCTCCCAAGGTGACACATCTGGCAATCGCCAGAAACAGATCAGGAGCATCAAC
 GCTTGGTTTCCCAGGGGCTTGGCTTAATGTATGGCTTCAAACCCATCGGGAGCCAC
 CACTGAACAGCTCCTGAAGGAACTGGAGCACGTCCCAGCCTTGGAATGGAAAGA
 GTTCACCTGTGGTGGAGGAATCAACAACGAGGGATCCCAGAACACGATCTTCA
 30 CCCCAGAAGCTGAGCCTCTTAGCCCCCACCACCCATTTCATTAGGCTGCCAG
 CTCTTTTCTTTACAATGCACCAGACCCCGCGGGGAAAGGGAAGGAGCGGTCTCA
 GTGCCCCAGTACCAAGGCCTGGATTATTCAATGAGGTGTCCGCTCCCTTTGTTGG
 CGGGGGAGGGGAGCGGGGGGGTCACAAGGCATCCAAACTCCACCTCTTTCCTCTG
 CCCTGCTGTGAAGGGGGGAGAGAACACCCCGCCTCGTGACAGGGGGGCTGGCACAG
 35 CCCGCCCTAGCCCTGAGGAGGGGGCGGGACAGGGGGGAGTCCTATAATTGGACCG
 GTCTGGGATCCGATCCCCTGCTCAGACCCTGGAGGCTAAGGACTTGTTTCGGAAG
 GAGCTGGTAAGACAAGCTGGGCTGGGGATTACCCAGGGACCTTGGTAGGATGT
 GGGCTGGGAACCTTGAGATCCCCCGGAGTCCAGGAAACAGGCACAAGAATTGGA
 AAAGCAGGCAGCACGATAGAAGTCTTGGGGGACAACTAAGGACTCGAGGTAA
 40 CTAGCCTTTGCCAGAGTCAGAGCAGGTGGAGGGGTACCTCCAGGAAGGAGTAC
 GGGACTGTCCGTGCACGGCGTACCGGCTCAACTAGGAACCATCCTATGGCGAAA
 AAACCTCGGGATGAGCCTTAGGCTGCTTTTTATATAAATACCTACTGATTTCCATCA
 CAGTCCCCAAGTAACCCGGACTGGTTTCAAACCTGTGGCTCCTCATGGCTGAGCTC
 CCTAAGTTCTGTAGTTGTGGGAGGGTACCACTTCGCAGGGATGGAGGACGATTA
 45 AAAATCGTGTTAAATTAAACACAAAATGGAAAGCAGGACTTAGCCGGGAAGAAAG
 AGGAATGTAAGCTGGACCACCCGCTGGCCCTCTGTGAAGTGGAATTTGAACCCTA
 GGAGAGGGAGCTGGAATTTTTTGGCAGCGGATCCACCCCGGGGTGCCGAGATAGC
 GAACTCGGCAAGGGGAGGTAAACAGACCTTTGGGAAGAGCGGGTGCTCTGTTTT
 GGAGATGTTTGTGATGGCTCACAGATCTGAGAAGGGAAGATGGGGTTCTCTGGG

- 51 -

TGGCCGGAGTCCCTCCACCCCCGCCCCCTGGTGTTCAAAGACAATTTTCCCTCC
GCAG

[00203] SEQ ID NO:10: DNA sequence including exons 2, 3 and 4 of the human APOE4
5 gene and 1500 nucleotides 3'UTR of the human APOE4 gene after exon 4 (4292
nucleotides) included in the "humanized" mouse ApoE construct inserted into the mouse
genome.

ACTGGCCAATCACAGGCAGGAAGATGAAGGTTCTGTGGGCTGCGTTGCTGGTCA
CATTCCTGGCAGGTATGGGGGGCGGGGCTTGCTCGGTTCCCCCGCTCCTCCCCCT
10 CTCATCCTCACCTCAACCTCCTGGCCCCATTACAGGCAGACCCTGGGCCCCCTCTTC
TGAGGCTTCTGTGCTGCTTCCTGGCTCTGAACAGCGATTTGACGCTCTCTGGGCCT
CGGTTTCCCCCATCCTTGAGATAGGAGTTAGAAGTTGTTTTGTTGTTGTTGTTTGT
TGTTGTTGTTTGTGTTTTTTTGAGATGAAGTCTCGCTCTGTGCGCCAGGCTGGAGTG
CAGTGGCGGGATCTCGGCTCACTGCAAGCTCCGCCTCCCAGGTCCACGCCATTCT
15 CCTGCCTCAGCCTCCCAAGTAGCTGGGACTACAGGCACATGCCACCACACCCGA
CTAACTTTTTTGTATTTTCAGTAGAGACGGGGTTTCACCATGTTGGCCAGGCTGGT
CTGGAACCTCCTGACCTCAGGTGATCTGCCCCGTTTCGATCTCCCAAAGTGCTGGGA
TTACAGGCGTGAGCCACCGCACCTGGCTGGGAGTTAGAGGTTTCTAATGCATTGC
AGGCAGATAGTGAATACCAGACACGGGGCAGCTGTGATCTTTATTCTCCATCACC
20 CCCACACAGCCCTGCCTGGGGGCACACAAGGACACTCAATACATGCTTTTCCGCTG
GGCGCGGTGGCTCACCCCTGTAATCCCAGCACTTTGGGAGGCCAAGGTGGGAGG
ATCACTTGAGCCCAGGAGTTCAACACCAGCCTGGGCAACATAGTGAGACCCTGT
CTCTACTAAAAATACAAAAATTAGCCAGGCATGGTGCCACACACCTGTGCTCTCA
GCTACTCAGGAGGCTGAGGCAGGAGGATCGCTTGAGCCCAGAAGGTCAAGGTTG
25 CAGTGAACCATGTTTCAGGCCGCTGCACTCCAGCCTGGGTGACAGAGCAAGACCC
TGTTTATAAATACATAATGCTTTCCAAGTGATTAAACCGACTCCCCCCTCACCCCTG
CCCACCATGGCTCCAAAGAAGCATTGTGTGGAGCACCTTCTGTGTGCCCCCTAGGTA
CTAGATGCCTGGACGGGGTCAGAAGGACCCTGACCCACCTTGAACCTTGTTCCACA
CAGGATGCCAGGCCAAGGTGGAGCAAGCGGTGGAGACAGAGCCGGAGCCCGAG
30 CTGCGCCAGCAGACCGAGTGGCAGAGCGGCCAGCGCTGGGAACTGGCACTGGGT
CGCTTTTGGGATTACCTGCGCTGGGTGCAGACACTGTCTGAGCAGGTGCAGGAGG
AGCTGCTCAGCTCCCAGGTACCCAGGAACTGAGGTGAGTGTCCCCATCCTGGCC
CTTGACCCTCCTGGTGGGCGGCTATACCTCCCCAGGTCCAGGTTTCATTCTGCCCC
TGTCGCTAAGTCTTGGGGGGGCTGGGTCTCTGCTGGTTCTAGCTTCCTCTTCCCAT
35 TTCTGACTCCTGGCTTTAGCTCTCTGGATATCTCTCTCTCAGCTTTGTCTCTCTCTC
TTCCCTTCTGACTCAGTCTCTCACACTCGTCCTGGCTCTGTCTCTGTCTTCCCTAG
CTCTTTTATATAGAGACAGAGAGATGGGGTCTCACTGTGTTGCCAGGCTGGTCT
TGAACCTTCTGGGCTCAAGCGATCCTCCCGCCTCGGCCTCCCAAAGTGCTGGGATT
AGAGGCATGAGCCACCTTGCCCCGGCCTCCTAGCTCCTTCTTCGTCTCTGCCTCTGC
40 CCTCTGCATCTGCTCTCTGCATCTGTCTCTGTCTCCTTCTCTCGGCCTCTGCCCCGT
TCCTTCTCTCCCTCTTGGGTCTCTCTGGCTCATCCCCATCTCGCCCCGCCCATCCC
AGCCCTTCTCCCCGCCTCCCACCTGTGCGACACCCTCCCCGCCCTCTCGGCCCGCAGG
GCGCTGATGGACGAGACCATGAAGGAGTTGAAGGCCTACAAATCGGAACTGGAG
GAACAACCTGACCCCGGTGGCGGAGGAGACGCGGGCACGGCTGTCCAAGGAGCT
45 GCAGGCGGCGCAGGCCCGGCTGGGCGCGGACATGGAGGACGTGCGCGGGCCGCC
TGGTGCAGTACCGCGGGCGAGGTGCAGGCCATGCTCGGCCAGAGCACCGAGGAGC

- 52 -

TGCGGGGTGCGCCTCGCCTCCCACCTGCGCAAGCTGCGTAAGCGGCTCCTCCGCGA
 TGCCGATGACCTGCAGAAGCGCCTGGCAGTGTACCAGGCCGGGGGCCCCGCGAGGG
 CGCCGAGCGCGGGCCTCAGCGCCATCCGCGAGCGCCTGGGGGCCCCCTGGTGGAAACA
 GGGCCGCGTGCGGGGCCGCACTGTGGGGCTCCCTGGCCGGCCAGCCGCTACAGGA
 5 GCGGGCCCAGGCCTGGGGGCGAGCGGCTGCGCGCGCGGATGGAGGAGATGGGCA
 GCCGGACCCGCGACCGCCTGGACGAGGTGAAGGAGCAGGTGGCGGAGGTGCGC
 GCCAAGCTGGAGGAGCAGGCCCCAGCAGATACGCCTGCAGGCCGAGGCCTTCCAG
 GCCCGCCTCAAGAGCTGGTTCGAGCCCCCTGGTGGAAAGACATGCAGCGCCAGTGG
 GCCGGGCTGGTGGAGAAGGTGCAGGCTGCCGTGGGCAACCAGCGCCGCCCCCTGTG
 10 CCCAGCGACAATCACTGAACGCCGAAGCCTGCAGCCATGCGACCCACGCCACC
 CCGTGCCTCCTGCCTCCGCGCAGCCTGCAGCGGGAGACCCTGTCCCCGCCCCCAGC
 CGTCCTCCTGGGGGTGGACCCTAGTTTAATAAAGATTACCAAGTTTCACGCATCT
 GCTGGCCTCCCCCTGTGATTTCTCTAAGCCCCAGCCTCAGTTTCTCTTTCTGCCC
 ACATACTGGCCACACAATTCTCAGCCCCCTCCTCTCCATCTGTGTCTGTGTGTATC
 15 TTTCTCTCTGCCCTTTTTTTTTTTTTTTAGACGGAGTCTGGCTCTGTCACCCAGGCTA
 GAGTGCAGTGGCACGATCTTGGCTCACTGCAACCTCTGCCTCTTGGGTTCAAGCG
 ATTCTGCTGCCTCAGTAGCTGGGATTACAGGCTCACACCACCACACCCGGCTAAT
 TTTTGTATTTTATAGTAGAGACGAGCTTTCACCATGTTGGCCAGGCAGGTCTCAAA
 CTCCTGACCAAGTGATCCACCCGCCGGCCTCCCAAAGTGCTGAGATTACAGGCCT
 20 GAGCCACCATGCCCCGGCCTCTGCCCCCTCTTTCTTTTTTTAGGGGGGCAGGGAAAGGT
 CTCACCCTGTACCCCGCCATCACAGCTCACTGCAGCCTCCACCTCCTGGACTCAA
 GTGATAAGTGATCCTCCCGCCTCAGCCTTTCCAGTAGCTGAGACTACAGGCGCAT
 ACCACTAGGATTAATTTGGGGGGGGGGGGGGTGGTGTGTGTGGAGATGGGGTCTGGC
 TTGTTGGCCAGGCTGATGTGGAATTCCTGGGCTCAAGCGATACTCCACCTTGG
 25 CCTCCTGAGTAGCTGAGACTACTGGCTAGCACACCACACCCAGCTTTTTTATTAT
 TATTTGTAGAGACAAGGTCTCAATATGTTGCCCAGGCTAGTCTCAAACCCCTGGG
 CTCAAGAGATCCTCCGCCATCGGCCTCCCAAAGTGCTGGGATTCCAGGCATGGG
 GCTCCGAGCCCCGGCCTGCCCAACTTAATAATACTTGTTCTCAGAGTTGCAACTC
 CAAATGACCTGAGATTGGTGCCTTTATTCTAAGCTATTTTCATTTTTTTCTGCTGT
 30 CATTATTCTCCCCCTTCTCTCCTCCAGTCTTATCTGATATCTGCCTCCTTCCCACCC
 ACCCTGCACCCCATCCCACCCCTCTGTCTCTCCCTGTTCTCCTCAGGAGACTCTGG
 CTTCTGTTTTCTCCTCACTTCTATCTTTTATCTCTCCCTCCTACGGTTTCTTTCTTT
 CTCCCCGGCCTGCTTGTCTTCTCCCCCAACCCCCCTTCATCTGGATTCTTCTTCTGCC
 ATTCAGTTTGGTTTGAGCTCTCTGCTTCTCCGGTTCCCTCTGAGCTAGCTGTCCCT
 35 TCACCCACTGTGAAGTGGGTTTCCCTGCCCAACCCCTCATTCTCTTTCTTTCTTTCTT
 TTTTTTTTTTTTTTTTTTTTTTTTTTTTGGAGACAGAGTCTTGCTCTGTTGCCAGCC
 TGGAGTGCAGTGGTGCAATCTTGGTTCACTGCAACCTCCACTTCCCAGATTCAAG
 CAATCTCCTGCCTCAGCCTCCAGAGTAGCTGGGATTACAGGCGTGTCCCACCAC
 ACCCGACTAATTTTTGTATTTTGGTAGAGACAAGGCTTCGGCATTGTT
 40

[00204] SEQ ID NO:11: a Frt PGKneo Frt cassette followed by an NdeI restriction enzyme site (CATATG) (1834 nucleotides) inserted in the “humanized” mouse ApoE construct between nucleotides 9272 and 9273 to allow for selection prior to recombinase-mediated removal of this cassette.

45 GAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCAGGTCTGAAGAGGAGTTTACG
 TCCAGCCAAGCTAGCTTGGCTGCAGGTCGTCGAAATTCTACCGGGTAGGGGAGG

- 53 -

CGCTTTTCCCAAGGCAGTCTGGAGCATGCGCTTTAGCAGCCCCGCTGGGGCACTTG
 GCGCTACACAAGTGGCCTCTGGCCTCGCACACATTCCACATCCACCGGTAGGCGC
 CAACCGGCTCCGTTCTTTGGTGGCCCCCTTCGCGCCACCTTCTACTCCTCCCCTAGT
 CAGGAAGTTCCCCCCCCGCCCCGCAGCTCGCGTCGTGCAGGACGTGACAAATGGA
 5 AGTAGCACGTCTCACTAGTCTCGTGCAGATGGACAGCACCGCTGAGCAATGGAA
 GCGGGTAGGCCTTTGGGGCAGCGGCCAATAGCAGCTTTGCTCCTTCGCTTTCTGG
 GCTCAGAGGCTGGGAAGGGGTGGGTCCGGGGGGCGGGGCTCAGGGGGCGGGGCTCAG
 GGGCGGGGGCGGGCGCCCCGAAGGTCCTCCGGAGGGCCCGGCATTCTGCACGCTTCA
 AAAGCGCACGTCTGCCGCGCTGTTCTCCTCTTCCCTCATCTCCGGGGCCTTTCGACCT
 10 GCAGCCTGTTGACAATTAATCATCGGCATAGTATATCGGCATAGTATAATACGAC
 AAGGTGAGGAACTAAACCATGGGATCGGCCATTGAACAAGATGGATTGCACGCA
 GGTTCCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGGCTATGACTGGGGCACAACAG
 ACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGGCGCCCGG
 TTCTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGC
 15 AGCGCGGCTATCGTGGCTGGCCACGACGGGGCGTTCCTTGCGCAGCTGTGCTCGAC
 GTTGTCACTGAAGCGGGAAGGGGACTGGCTGCTATTGGGGCGAAGTGCCGGGGGCAG
 GATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATG
 CAATGCGGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTTCGACCACCAAGC
 GAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCA
 20 GGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAAGTGTTCGCCAG
 GCTCAAGGCGCGCATGCCCCGACGGCGATGATCTCGTCGTGACCCATGGCGATGC
 CTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTTCATCGACTGT
 GGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGAT
 ATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTA
 25 TCGCCGCTCCCGATTTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTC
 TGAGGGGATCAATTCTCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTT
 GCCAGCCATCTGTTGTTTGCCCCCTCCCCCGTGCCCTTCCTTGACCCTGGAAGGTGCC
 ACTCCCCTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTA
 GGTGTCAATTCTATTCTGGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGGAGGATT
 30 GGGAAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGG
 CGGAAAGAACCAGCTGGGGGCTCGACTAGAGCTTGCGGAACCCTTCGAAGTTCTCT
 ATTCTCTAGAAAGTATAGGAACTTCCATATG

[00205] SEQ ID NO:12: 3' homology arm (5166 nucleotides) included in the
 35 "humanized" mouse ApoE construct inserted into the mouse genome.

AAACCTGATGGAGAAGATACAGGCCTCTGTGGCTACCAACCCCCATCATCACCCC
 AGTGGCCCAGGAGAATCAATGAGTATCCTTCTCCTGTCTTGCAACAACATCCATA
 TCCAGCCAGGTGGCCCTGTCTCAAGCACCTCTCTGGCCCTCTGGTGGCCCTTGCTT
 AATAAAGATTCTCCGAGCACATTCTGAGTCTCTGTGAGTGATTCCAATCAGCTTC
 40 AGCCTCAGTTTATTGTTTTTTGCCTTACCTAGCACACATTCCATGGCCCTGTCACT
 ATCTGTAGAGGGAGGTGGTTTTTGCAGCAATAGAAATGAAGCCTAGGACCTAGCA
 ACATAAAAGAACAAGTGATCTACCACTGAGCCACGCCACAGCCCCCTCACTGGG
 GGATTCTAGGCAGGGGGCTCTACCACTGAGCCACCCGCGAGCCCCCTCACTGGGGAA
 TCATATCTACCACTGAGTCACGCCCTCCAGCCCCCTCACTACGGGAATTCTAGTC
 45 AGTAGCTCTACCACTGAGCCACACCCACAGCCTCTGGGGCTCTTCACCGCCCCCT
 ACCCCTGGATTCTAGGCATGGGCTCATTTTATTTATTTATTTATTTAAGATTGTTT
 ATCTTATGTATAAGGTACACTGCAGCTGTCTTCAGGCGTCAGGTCCCATTACAGA

- 54 -

TGGTTGTGAGCCACCATGTGGTTGCTGGGAATTGAACTCAGGACTTATAGAAGAG
 TAGTCAGTGCTCTTAAGTCTGAGCCATCTCTCCAGCACCCAGTACAGGCTCTTCT
 ATTTAGCTATATCCACCCCTTCTTTTATAGTCTGAAATAGGATCTCAACTGATTTTCC
 TTGCACTCCCTCTAGCCTAGTTTGGTCTTGAATATTTGAATCTTTGTTTTCAAATC
 5 AATCTCTACAGGAACTGAGAAAGGCATGTACCACTTCATGTGGGTCAGTTGGGCT
 ACTTTTCCCAACTTCCCAAGCACCCACTGCACAGCTATGCCTTGAATCAATCAAC
 ATGTAAGAGACCAGGGTCGCCAGGCGGTGTTTACTTTTCTGGTTGTCTTATCTCTC
 CTCCTCCGCTCTAGTCTTATCTGACACCCCTCTCCTTGCCTTGTCTCTCCTCTTTTTC
 CCTTCTAGGCTTCCTTTTCTGGCTTCCTGTTTTCTGATCCTCTGTTATCTCACCCCT
 10 CCCGCGGTTTCTTTTGGCTCTGGGCTTTGGTTGGCGGTTTCTACGGTTTCTACGTG
 GCTTTTGGAACTCAGCCTTTCTCCCTTGGCTCTGAAGTTAGCTGGATCTTTGCTCC
 CTCTGGGTCATGGGGCCTTAGCCCCATTCTTTCTCCCTGCCTGTGCTGCATGCCT
 TTTGACTTTCCAGCAAGTGTATGGAGAGTGAGTTCAGGCTGGGGACACAAAAC
 CATTCTCCCCATGTCCTGGTACTCAAAGGGGTCATGGTGGAAGCTGGAGAGCCCC
 15 TGGCTGGCTTCTCCTCCACCCCTCAGTTCTCAGGGACTCAGCAGGGCTCCAC
 TAACAGGGGCAGGCTAGGGCTTGAGCTGTGTCTTGGGTCGGGGCCAAGGCTTCAG
 AACTCAACTGCCTCTGGCACACCCCGAGCCTGCAGCTTTTCTGTCATCAAATC
 AGCATTATCTGGAGGCAGGCACCACTCCACACATGACTCATTAGGCCCAATGA
 GAAGATGGGTGCGTGGGCTAGTGACAGGGGCCCTAGACAGCCACACTTCATGCCC
 20 AGGGGCTAGGAGCACACCCCCAGAGCCTCACTACTCTCAAATATCAAGATGAGG
 GGAGAGTATAGAGGGAATGTCTCCCTCTGAAGACCTGAATTATTGTGATGTTATT
 TGAGCCACGCTGGCCTTGAACCTCTGAACCCCTCCTGCCTCATCTTCAAAGGCTGGA
 ATTACAGGTTCGCGCCACTAGGCCTATCTGAGAACTTAGTTAATTCTACAGAAGA
 GAGTTTGTTTTCACTGGTTTGAACGAGGCCTCGTGTACCCAGAGCTACTCTTTTG
 25 CCAACTCACTGTAGAGCCAAGGATGACCTTGAACCTCTGGTCTTCTGCTCCGAG
 TCCTCGGTACTGGGTAGACAATGTGTGATCCTAACCCCCAGTTTTATGTGGTGCT
 ATACAGATGGCATCCAGGGTTTCTGTCATGCTGGACAGGTCATCAACCAACCGA
 GCCACATCCTCCTCATCATCATCACTTTGTTGTTGGTTTTCAATCCAGAGCTCATG
 GAGCCCAAGCTGGCCTCAATCTATATAACCAAGACTGTGCCTGGTCTTCTGCTCT
 30 CTACCTAACAATGATGGTGGGATGCAGGGATGTACAACCAGGAGCAGAGCCTT
 ACTTCTAAACGAAGAAGGAACCCACCTCCCTGTGGGCAGACCTGGAGGTGGGG
 CAAGGACCACAGAAAGACATTACAGAAGTAGGATCGTGAAGGAAGTCATGGAG
 GCCAGCCTGTTGTACAGAGTGAGTTCCAGGACAGCCAGGGCTACACAGAGGAAA
 ACAAGAAGGAAAAAAAAAAAAAAAAAAAAAAAAAGAACTGAATGACTAGCAGTTTTAGA
 35 ACCTTAGCTGTGTGCTTCCCGTACCCTACCTGTGGCACAGGAAGCCCTTGTTGCT
 AAGAGTAGGATGACACTGGAAGCACCAAGCACTGGGCAGAGTAAGGGGGGAAAT
 CTGTTACATTATTCAGATGGGCGCTTGAGGACTGAGCAGGACTCCTTTCAAGAAG
 CAAAAGGGTCAGGCCTGGTGCCACAGGGACTGGAAGCTAGCTAGCGCCGAGTT
 GGCCCCAGAGATGTCGCAACCCAGCCAGGGTCGAGAATCTGTTCCACCCCTTTCA
 40 CAACCATCCCCCTGTTGTCGTCGTCCTCCACCCCAACCCCACTGACACG
 TGGGTTGCAGGGGGCACCAGGCCAGCCAACCTAGAGTCTGGGGCCCTTAGCCACC
 AGCTGCCAGGGGGTCACTGTGGTCAATGACAGCTCTGGGGGAGGGGGGGAGAA
 GGGCCTTGGAAGCTAGCCTGAGAGAAAGGATGTTGTGGAAGGAGGGGGGAGGGA
 GGCAAGTTTAGGGCCTGCAGGGGGCCTAGGAGGGCCCCACAAGACCTAAAAACGGG
 45 GGAAGGGGGGTTGTGCCAGTTAGGGGACACTATGGAGCTCTGCAAGCTAAGAGG
 CTCTTAGCTTCTTTGCAGTTTGTACTAGCTGAAGAGGCAACTTCTAAGGAAGGGA
 GATGAGGGGATGCCAAGATCCCAGAGAGCATCCGAGGAGGTCTGAGGGTGTGCA
 GATGCAAAGGCATTGGAGGTGAAGGGAGCCAGGGTGCAGCATCCGGGACAGAA
 TGTGAGCTGAGGCTCCTGGTCAAGGAGAAGGTAGAGAAGAGCTAACCTGAGGAT

- 55 -

GCAGTGTGAGCTAGGGGTGAGATGGGGGTGAGGGGAGTTGTTTGTAAGACCCCC
 CCCCTTAAGGTGGGACAGCCTCAGAGAGAGAGTGTAGTAGGCAGAGCAGCCAAG
 GCTGGGTGGAGATCAATGAGATTTGGAAGTGAGGATGCTGACCAGTGACGAGCC
 TTGGGCCTAAATAAAAAAGCCTGGATGTGGGATCTGCCTCCCAGTATCGACCAGA
 5 ATGACAGAAGAGAGTGGGCTGGTTGTGTTGGTGTGTTGGTGCATGCCTGTAATCCCA
 GCAACTCACTAGAGAGGCAGAGGCAGGAGCATCACAAATTCCAGGCCAGCCAA
 AAAGCCTATGTAAAAAAGAGAAAAAAGAAAAAAGAAAAAGTAGGT
 GGACACAGAGACAAGGGGGGAGGCTCAGGGGGGAGGGGCGACCAGCTTGCTCCGCC
 CCCTCCCCAACCGGTTAAACCTCTGTGCAGGATCCTCCCACCGCCATGGGGCCTCC
 10 TGAGAGATCCTTAGATCCAGGTTAGTGCATAGGAAAGTGTCCCCCCTACTACCTAC
 AGCTAAGGGATTGGGGTGGTGGGATCATGGTGGAGGGCGGTGGTGAATACTAGC
 GATGTCCCCCGCTACCCGTGCGTCTGCCTCCAGGGGTGCCCCCTCCAACCAGGATGA
 GGCTCTTCATCGCTCTTCCTGTCCTGATTGTGGTCGTAGCCATGACCTTGGAAGGT
 AAGAAAGAGCCTTGGAAGGTAAGAAAGAGGGCTTGGAAGTGTGAAGTTGGCCTTG
 15 TGCCTGCGGCCCAGGCTTAGAAGACCCTCGAGGAGGGCTCTGAGGTCCCTTTCTG
 TGTCATCATTCCACTACCGCCCTCCCATCGTCCCCCATCCACCTGCCAGGTGCCT
 TATTTTTGTGTCAAAGTGGGTGCTGAAGGAGGCAACTCTGTCCAGAAAAGACGC
 AGTAACCAATGACCTAGGATACCACCCTTTGGAATTGGCTAATCTTCCTAGAAGG
 GGCGGAGCGTAAAAACAAGGAGGTGAGAGGTGCAGTAAATCAAGTGTCCAAT
 20 ACCCTCCCCCATGCTAATGAGTTTGCTCGCAACCCTCTCGCGGCAGGCCAGCCC
 CCGCCCAGGCGGCCCGGATTGTCCGGAACATTGGAGAGCATACCGGATAAAC
 TGAAGGAGTTTGGGAACACTTTGGAAGACAAGGCCCGGGCAGCCATTGAACATA
 TCAAACAGAAGGAAATTTTGACCAAGACCCGGTTAGGACCTTTCAGGGCACGGG
 CGGGTGGTGTGTGTGTGTGTGCGTGC GCGCGCGCCCCGTGTGTAAAAGCCCTAGCA
 25 GACAGTTCCACACTGACACAATGGGGGAACTGCACCAGAGTGTGTTGACACTTTCC
 CTGAAGTCATAGAACTGTATCTGAAGTCATTGAACTGGATGTCAAAGTGCTCGTA
 GTGTGGAGACAGGCGGTGTAACCTCCAGCCAACCTGTTAGAGATGTTTCCAAGTCC
 TAGTGAAGGGCCAAGCTAGGCGGCTGACTGGTTAGGACAGACCCTGACCCCTCC
 CTGTGTACTCTTGAGACAGGTCATGACTTGAGTCTCCGAGACAGAGAAAGAATGT
 30 AGGAGAGTTGGGGCAGGGGCACAGCAGAAGCTGTACAGGCCTGGGCTCTGCAGT
 TTACACTGGCCAAAGAGAGATTAGGGCATGCTGGGTAAAGAACTAGCCAGGCAG
 TGGTGGCGCACACCTTTGATCCCAGTATTCATGAGGCAGAGGCAGGCAGATCTCT
 TTGAGGCCAGCCTGATTGGAGCTAGTTCTAGGAAAGCCAGGGCTACACAGAGAA
 ACCCTGTCTCAACACCACCACCACCCCCC

35

[00206] SEQ ID NO:13: wild-type amino acid sequence-mouse Apoe

MKALWAVLLVTLLTGCLAEGEPEVTDQLEWQSNQPWEQALNRFWDYLRWVQTLS
 DQVQEELQSSQVTQELTALMEDTMTEVKAYKKELEEQLGPVAEETRARLGKEVQA
 AQARLGADMEDLRNRLGQYRNEVHTMLGQSTEEIRARLSTHLRKMRKRLMRDAED
 40 LQKRLAVYKAGAREGAERGVSAIRERLGPLVEQGRQRTANLGAGAAQPLRDRAQA
 FGDRIRGRLEEVGNQARDRLEEVREHMEEVRSKMEEQTQQIRLQAEIFQARLKGWFE
 PIVEDMHRQWANLMEKIQASVATNPITPVAQENQ

45 [00207] SEQ ID NO:14: amino acid sequence-human APOE3

MKVLWAALLVTFLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDY
 LRWVQTLSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRAR
 LSKELQAAQARLGADMEDVCGRLVQYRGEVQAMLGQSTEELRVRLASHLRKLRKR

- 56 -

LLRDADDLQKRLAVYQAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPL
 QERAQAWGERLRARMEEMGSRTDRDLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQ
 ARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTS AAPVPSDNH

5 [00208] SEQ ID NO:15: APOE4p (299 amino acids)

KVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQTLSEQVQEELLSSQ
 VTQELRALMDETMKELKAYKSELEEQLTPVAEETRARLSKELQAAQARLGADMED
 VRGRLVQYRGEVQAMLGQSTEELRVRLASHLRKLRKRLLRDADDLQKRLAVYQAG
 AREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEE
 10 MGSRTDRDLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQ
 WAGLVEKVQAAVGTS AAPVPSDNH

[00209] Any patents or publications mentioned in this specification are incorporated
 herein by reference to the same extent as if each individual publication is specifically and
 15 individually indicated to be incorporated by reference.

[00210] The genetically modified mice and methods of use described herein are presently
 representative of preferred embodiments, exemplary, and not intended as limitations on the
 scope of the invention. Changes therein and other uses will occur to those skilled in the art.
 Such changes and other uses can be made without departing from the scope of the invention
 20 as set forth in the claims.

- 57 -

WHAT IS CLAIMED IS:

1. A genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease, the genome of the mouse comprising: 1) a DNA sequence encoding a human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p) operably linked to a promoter, wherein the mouse expresses human APOE4p and mouse Trem2p.
2. The genetically modified mouse of claim 1, wherein the APOE4p comprises an amino acid sequence of: SEQ ID NO:1, or the APOE4p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:2 under highly stringent hybridization conditions.
3. The genetically modified mouse of claim 1, wherein the mouse Trem2p comprises an amino acid sequence of: SEQ ID NO:3, or the mouse Trem2p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:4 under highly stringent hybridization conditions.
4. The genetically modified mouse of claim 1, wherein the genetically modified mouse is a B6(SJL)-*ApoE*^{tm1.1(APOE*4)AdinJ} *Trem2*^{em1AdinJ}/J mouse whose genome comprises: 1) a DNA sequence encoding human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding mouse Trem2 protein having a mutation p.R47H (Trem2p) operably linked to a promoter, wherein the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p, and wherein the mouse expresses human APOE4p and mouse Trem2p.
5. A method for screening for a compound for use in the treatment of Alzheimer's disease, comprising:
administering a compound to a genetically modified mouse of any one of claims 1 to 4; and

- 58 -

assessing an effect of the compound on the treatment of one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse.

6. The method for screening for a compound for use in the treatment of Alzheimer's disease of claim 5, wherein assessing an effect of the compound comprises comparing the effect of the compound on the genetically modified mouse of any one of claims 1 to 4 with a control.

7. The method for screening for a compound for use in the treatment of Alzheimer's disease of claim 6, wherein the control comprises:

administering the compound to a mouse which does not express human APOE4p and mouse Trem2p; and

assessing an effect of the compound on the mouse.

8. The method for screening for a compound for use in the treatment of Alzheimer's disease of claim 6 or 7, wherein the control comprises:

administering the compound to a wild-type C57BL/6J mouse; and

assessing an effect of the compound on the wild-type C57BL/6J mouse.

9. The method for screening for a compound for use in the treatment of Alzheimer's disease of claim 6 or 7, wherein the control comprises:

administering the compound to an APOE3-expressing mouse; and

assessing an effect of the compound on the APOE3-expressing mouse.

10. A genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease substantially as described herein.

11. A method for screening for a compound for use in the treatment of Alzheimer's disease substantially as described herein.




FIG. 1




FIG. 2




FIG. 3A




FIG. 3B




FIG. 3C





FIG. 4






FIG. 3A